Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
486	BER000786	BER000825	6/29/2001	[redacted]	I, A, H
487	BER000681	BER000682	7/24/2001	[redacted]	I, A, H
488	BER000558	BER000608	7/26/2001	[redacted]	I, A, H
489	CUBT0000411	CUBT0000528	11/19/2010	[redacted]	NE, H
490	CUBT0000585	CUBT0000618	11/7/1997	[redacted]	
491	CUBT0000675	CUBT0000682	1999	Sieradzki et al., "The Development of Vancomycin Resistance in a Patient with Methicillin-Resistant Staphylococcus Aureus Infection," N.E.J.M., 340(7):517-523	I
492	CUBT0000529	CUBT0000546	9/3/2003	[redacted]	I
493	CUBT0000689	CUBT0000693	8/31/1983	[redacted]	H, A-A, I
494	LLY00004008	LLY00004009	9/27/1983	[redacted]	H, A-A, I
495	CUBT0000696	CUBT0000697	5/13/1987	[redacted]	H, A-A, I, R
496	CUBT0000698	CUBT0000700	5/3/1984	[redacted]	I, A-A, H
497	CUBT0000703	CUBT0000839	03/1989	[redacted]	
498	CUBT0003861	CUBT0004116		File History for U.S. Patent 5,912,226	I, R
499	LLY00005686	LLY00005691	12/2/1985	[redacted]	H, A-A
500	CUBT0001331	CUBT0001331	8/29/1985	[redacted]	H, A-A
501	CUBT0001332	CUBT0001478	5/16/1983	European Patent Application 0 095 295 A1	H, A-A, I
502	CUBT0001567	CUBT0001568	3/11/1986	Ltr from C.M. Hudson to European Patent Office	H, A-A, I, X
503	LLY00004083	LLY00004087	8/6/1984	[redacted]	H, A-A
504	CUBT0001577	CUBT0001577	6/7/1983	[redacted]	H, A-A
505	LLY00005586	LLY00005586	10/5/1984	[redacted]	H, A-A, I
506	LLY00005590	LLY00005590	10/25/1984	[redacted]	H, A-A, I
507	LLY00005594	LLY00005594	12/17/1984	[redacted]	H, A-A, I
508	LLY00005602	LLY00005602	2/21/1985	[redacted]	H, A-A, I
509	LLY00005615	LLY00005615	6/5/1985	[redacted]	H, A-A, I
510	LLY00000504	LLY00000504	8/7/1985	[redacted]	H, A-A, I
511	CUB00548245	CUB00548254		[redacted]	I, H, A-A, X
512	CUB00548255	CUB00548260		[redacted]	I, H, A-A, A-D

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
513	CUB00568119	CUB00568552	3/29/1989	[redacted]	R – COMPILATION OF MULTIPLE DOCUMENTS
514	CUB01737634	CUB01737641	2/24/1987	[redacted]"	H, A-A, I
515	CUBT0001673	CUBT0001674	7/11/1988	[redacted]	H, A-A, X
516	LLY00003902	LLY00003907		[redacted]	H, A-A
517	LLY00005301	LLY00005328	1/15/1987	[redacted]	H, A-A
518	CUBT0001710	CUBT0001871	11/19/2010	[redacted]	NE, I, H
519	CUBT0002052	CUBT0002183	10/7/2010	[redacted]	NE, H
520	CUBT0002216	CUBT0002225	9/11/2000	Declaration of Frederick B. Oleson	C, I
521	CUBT0002226	CUBT0002231	2009	Chambers et al., "Relationship between Susceptibility to Daptomycin in Vitro and Activity in Vivo in a Rabbit Model of Aortic Valve Endocarditis," Antimicrobial Agents and Chemotherapy, 53(4):1463-1467	I
522	CUBT0002232	CUBT0002241	1996	Michiels and Bergeron, "Differential Increased Survival of Staphylococci and Limited Ultrastructural Changes in the Core of Infected Fibrin Clots after Daptomycin Administration," Antimicrobial Agents and Chemotherapy, 411(1):203-211	I
523	CUBT0001890	CUBT0001901	12/5/2000	Response to 7/21/00 written opinion issues by International Preliminary Examining Authority	I
524	CUBT0009767	CUBT0009768	09/1989	Lee et al., "Factors Influencing Daptomycin Serum Protein Binding," Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 1346 (Pg 329)	
525	CUBT0002012	CUBT0002017	7/19/2000	[redacted]	H, I
526	CUBT0002018	CUBT0002031	9/29/2000	[redacted]"	H, I, DE - DRAFT
527	CUBT0002032	CUBT0002034	1986	Black Abstract Program and Abstracts of the Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherap (Pg 261)	I
528	CUBT0002040	CUBT0002045	2009	Gikas et al., "Development and Validation of a UPLC-UV method for the Determination of Daptomycin in rabbit plasma," Biomed Chromatography, 24:522-527	I
529	CUBT0002046	CUBT0002051	2009	Gikas et al., "Simultaneous quantification of daptomycin and rifampicin in plasma by ultr performance liquid chromatography: Application to a pharmacokinetic study," J. Pharmaceutical and Biomedical Analysis (pg 1-6)	I
530	CUBT0002248	CUBT0002253	9/11/2008	[redacted]	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
531	CUBT0002857	CUBT0002920		Center for Drug Evaluation and Research, Approval Package for: Application Number 21-572	I
532	CUBT0002921	CUBT0003121		File History for U.S. Patent 5,912,226	I, R
533	CUBT0003122	CUBT0003402		File History for 10/747,485	I, R
534	CUBT0002349	CUBT0002373	11/27/2000	Cubist Document, www.cubist.com/v2/html/sci_dapto.html	I, X, R – COMPILATION OF MULTIPLE DOCUMENTS
535	CUBT0002374	CUBT0002418	12/16/2003	[redacted]	I, A-D - DRAFT
536	CUBT0002419	CUBT0002421	1988	USAN and USP Dictionary of Drug Names, pg 161-162	I, H
537	CUBT0002608	CUBT0002609		[redacted]	A-D – INACCURATE DESCRIPTION
538	CUBT0002645	CUBT0002668	10/6/2000	[redacted]	
539	CUBT0002669	CUBT0002672	7/2/2003	Business Wire Press Releases: "Cubist Pharmaceuticals Purchases 1% Reduction in Cidecin Royalty Rate from Lilly with Common Stock," and 7/22/03 "Cubist Pharmaceuticals and Lilly Complete Royalty Rate Transaction"	I, H
540	CUBT0002673	CUBT0002822	2008	Cubist 2008 Annual Report	I
541	CUBT0002823	CUBT0002826		[redacted]	I
542	CUBT0003470	CUBT0003473	8/10/2010	Notice of Rule 30(b)(6) Deposition of Cubist, Cubist v. Teva No. 09-189	I, H, NE
543	CUBT0003512	CUBT0003519	9/11/2000	Declaration of Francis P. Tally	
544	CUBT0003476	CUBT0003494	12/19/2002	Excerpts from Cubist NDA 21-572	X, R
545	CUBT0003673	CUBT0003673	11/26/1985	[redacted]	H, A-A, X
546	CUBT0003693	CUBT0003696	5/9/1985	Appendix C: Compound LY146032 Analytical Characterization	H, A-A, X
547	CUBT0003697	CUBT0003701	3/19/1986	Appendix C.3: Compound LY146032 Analytical Characterization	H, A-A, X
548	CUBT0003702	CUBT0003708		Appendix A: Analytical Characterization Report	H, A-A, X
549	CUBT00015366	CUBT00015443	10/15/2010	[redacted]	NE, H
550	CUBT0003810	CUBT0003845	11/19/2010	[redacted]	NE, H
551	CUBT00015444	CUBT00015459	12/17/2010	[redacted]	NE, H
552	CUBT0003860	CUBT0003860	4/18/2006	Certificate of Correction re RE39,071	C
553	CUBT0004134	CUBT0004141	2000	Boden and Pattenden, "Total Syntheses and re-assignment of configuration of the cyclopeptides lissoclinamide 4 and lissoclinamide 5 from Lissoclinum patella," J. Chem. Soc. Perkin Trans. 875-882	
554	CUBT0003709	CUBT0003738	10/5/2010	[redacted]	NE, H, I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
555	CUBT0003803	CUBT0003809	2000	Orwa et al., "Liquid chromatography of polymyxin B sulphate," J. Chromatography A, 870:237-243	
556	CUBT0004166	CUBT0004213	11/19/2010	[redacted]	NE, H, I
557	CUBT0004214	CUBT0004214		[redacted]	NE, H, I
558	CUBT0004215	CUBT0004218	12/2003	Sterile Vancomycin Hydrochloride, USP, American Pharmaceutical Partners Inc.	I
559	CUBT0004219	CUBT0004254	06/2010	Zyvox Package Insert	
560	CUBT0004265	CUBT0004292	08/2010	Cubicin Package Insert	
561	CUBT0004293	CUBT0004298	6/7/2007	[redacted]	I
562	CUBT0004324	CUBT0004455	12/1998	Module 2F; Nonclinical Written Summary Pharmacology and Toxicology Information	I
563	CUBT0004461	CUBT0004470		Chart: Plasma PK of Daptomycin in Rabbits 12 and 18 mg/kg, IV bolus Chambers' Data	I, H
564	CUBT0004471	CUBT0004477		Chart: Plasma PK of Daptomycin in Rabbits 10 and 20 mg/kg, IV bolus Dr. Chambers' Data	I, H
565	CUBT0004478	CUBT0004495		Chambers et al., Redline of The Relationship Between Daptomycin Susceptibiity and Responses to Therapy	I, H
566	CUBT0004303	CUBT0004320		Chambers et al., Redline of The Relationship between Susceptibility to Daptomycin in Vitro and Activity in Vivo in the Rabbit Model of Aortic Valve Endocarditis	I, H
567	CUBT0004321	CUBT0004323	9/10/2008	General comments on chambers aortic valve endocarditis Draft 2	I, H
568	CUBT0004496	CUBT0004497	2/24/1998	Chart: Daptomycin "Not for GMP Use"	H, I
569	CUBT0004645	CUBT0004645	3/2/1998	Chart: Daptobul	H, I
570	CUBT0004648	CUBT0004649	3/12/1998	[redacted]	H, C, P, I
571	CUBT0004650	CUBT0004651	3/2/1998		H, C, P, I
572	CUBT0004652	CUBT0004652	9/10/1998		H, C, P, I
573	CUBT0004653	CUBT0004653	6/29/1999		H, C, P, I
574	CUBT0004654	CUBT0004659		[redacted]	X, A-D, H, C
575	CUBT0004660	CUBT0004660	11/26/1990		H, A-A
576	CUBT0004661	CUBT0004661	8/24/1998		I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
577	CUBT0004498	CUBT0004500	9/24/1998	[redacted]	I, X
578	CUBT0004501	CUBT0004504		[redacted]	H, A-A
579	CUBT0004505	CUBT0004588	4/24/2007	Patent Application; High Purity Lipopeptides	C
580	CUBT0004589	CUBT0004609	11/13/2009	Request for Continued Examination Transmittal (Application 11/739,180)	C
581	CUBT0004613	CUBT0004625	11/1/1996	Boaretti and Canepari, Identification of daptomycin-binding proteins in the membrane of Enterococcus hirae	I, A-D – INACCURATE DESCRIPTION
582	CUBT0004626	CUBT0004627	5/2/1997	[redacted]	I
583	CUBT0004628	CUBT0004629	7/10/1998	[redacted]	I
584	CUBT0004644	CUBT0004644	8/11/1998	[redacted]	I
585	CUBT0004646	CUBT0004647	2/3/2000	[redacted]	I
586	CUBT0005278	CUBT0005281	4/8/1997	[redacted]	H, I
587	CUBT0005284	CUBT0005285	8/7/1997	[redacted]	I
588	CUBT0005286	CUBT0005288	6/2/1998	[redacted]	I
589	CUBT0005289	CUBT0005313	5/25/1982	U.S. Patent 4,331,594	
590	CUBT0005363	CUBT0005365	6/19/1998	[redacted]	H, I
591	CUBT0004679	CUBT0004682	7/10/2003	Supplemental Amendment re U.S. Patent 5,912,226	C
592	CUBT0004683	CUBT0004746	2/26/2008	U.S. Patent 7,335,726	I
593	CUBT0005031	CUBT0005277		File History of 11/739,180	R, C, X
594	CUBT0005282	CUBT0005283		35 U.S.C. 102 Conditions for patentability; novelty and loss of right to patent	NE
595	CUBT0005594	CUBT0005857	11/18/2010	[redacted]	NE, I, H
596	CUBT0005993	CUBT0006000	4/3/2000	[redacted]	I, H
597	CUBT0006588	CUBT0006589	11/21/2000	[redacted]	I
598	CUBT0006590	CUBT0006681	11/21/2000	[redacted]	I
599	CUBT0006682	CUBT0006690	2004	Dvorchik et al., "Population Pharmacokinetics of Daptomycin," Antimicrobial Agents and Chemotherapy, 48(8):2799-2807	I
600	CUBT0006691	CUBT0006700	10/28/2004	[redacted]	I
601	CUBT0006701	CUBT0006712	11/25/2008	[redacted]	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
602	CUBT0006713	CUBT0006840	10/3/2000	[redacted]	I
603	CUBT0006841	CUBT0006952	11/21/2000	[redacted]	I
604	CUBT0005858	CUBT0005871	6/5/2001	[redacted]	I
605	CUBT0005872	CUBT0005874	3/12/2003	[redacted]	I
606	CUBT0005875	CUBT0005876	3/21/2003	[redacted]	I
607	CUBT0005877	CUBT0005900	3/26/2003	[redacted]	I
608	CUBT0005901	CUBT0005906	3/14/2002	[redacted]	I
609	CUBT0005907	CUBT0005918	4/11/2003	[redacted]	I
610	CUBT0005919	CUBT0005964	09/1999	[redacted]	I
611	CUBT0005965	CUBT0005979		[redacted]	I
612	CUBT0005980	CUBT0005982	5/16/2005	[redacted]	I
613	CUBT0005983	CUBT0005992	6/21/2006	[redacted]	I
614	CUBT0006001	CUBT0006005	2003	Dams and Huestis, "Matrix Effect in Bio-Analysis of Illicit Drugs with LC-MS/MS: Influence of Ionization Type, Sample Preparation, and Biofluid," J. Am. Mass. Spectrom, 14:1290-1294	I
615	CUBT0006006	CUBT0006525	12/2010	[redacted]	I, H
616	CUBT0006526	CUBT0006529	2003	Annesley, "Ion Suppression in Mass Spectrometry," Clinical Chemistry, 49(7):1041-1044	I
617	CUBT0006530	CUBT0006541	2003	Dvorchik et al., "Daptomycin Pharmacokinetics and Safety Following Administration of Escalating Doses Once Daily to Healthy Subjects," Antimicrobial Agents and Chemotherapy, 47(4):1318-1323	I
618	CUBT0006542	CUBT0006546	2003	Sakoulas et al., "Evaluation of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus Aureus" Antimicrobial Agents and Chemotherapy, 47(5):1714-1718	I
619	CUBT0006552	CUBT0006553		Aptuit Document: Physical and Analytical Chemistry	I, H
620	CUBT0006554	CUBT0006579	10/12/2010	Cubicin 500 mg Drug Product Certificate of Analysis	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
621	CUBT0006953	CUBT0006956	1992	Rice et al., "In vivo Activity of the Combination of Daptomycin and Fosfomycin Compared with Daptomycin Alone Against a Strain of Enterococcus faecalis with High-Level Gentamicin Resistance in the Rat Endocarditis Model," Diagn Microbiol Infect Dis, 15:173-176	
622	CUBT0006999	CUBT0007002	1986	Eliopoulos et al., "In Vitro and in Vivo Activity of LY 146032, a New Cyclic Lipopeptide Antibiotic," Antimicrobial Agents and Chemotherapy, 30(4):532-535	
623	CUBT0007003	CUBT0007008	2008	Moellering, "Current Treatment Options for Community-Acquired Methicillin-Resistant Staphylococcus aureus Infection," CID 46(1):1032-1037	
624	CUBT0007011	CUBT0007116	11/19/2010	[redacted]	NE, H
625	CUBT0007190	CUBT0007193	8/13/1991	[redacted]	
626	CUBT0007290	CUBT0007291	7/25/2006	[redacted]	I, H
627	CUBT0007292	CUBT0007293	5/13/2005	[redacted]	
628	CUBT0007145	CUBT0007147	11/25/1998	[redacted]	H
629	CUBT0007148	CUBT0007153	2000	Oleson et al., "Once-Daily Dosing in Dogs Optimizes Daptomycin Safety," Antimicrobial Agents and Chemotherapy, 44(11):2948-2953	
630	CUBT0007154	CUBT0007157	1989	Hindes et al., "Treatment of Experimental Endocarditis Caused by a β-Lactamase-Producing Strain of Enterococcus faecalis with High-Level Resistance to Gentamicin," Antimicrobial Agents and Chemotherapy, 33(7):1019-1022	I
631	CUBT0008786	CUBT0008790	12/1998	Module IIB; Nonclinical Written Summary Pharmacology and Toxicology Information	I, A-D - PARTIAL DOCUMENT
632	CUBT0008670	CUBT0008678	11/28/2001	[redacted]	I
633	CUBT0008679	CUBT0008688		F. Oleson C.V.	I
634	CUBT0008689	CUBT0008698	1997	Ole-Mapenay et al., "Aspects of the Pharmacokinetics of Doxycycline Given to Healthy and Pneumonic East African Dwarf Goats by Intramuscular Injection," Veterinary Research Communications, 21:453-462	I
635	CUBT0008704	CUBT0008706	1993	Davies and Morris, "Physiological Parameters in Laboratory Animals and Humans," Pharmaceutical Research, 10(7):1093-	I
636	CUBT0008707	CUBT0008718	12/1985	[redacted]	I
637	CUBT0008719	CUBT0008776		[redacted]	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
638	CUBT0008886	CUBT0008941	12/15/1998	[redacted]	
639	CUBT0008944	CUBT0008944	2/9/00	[redacted]	I, H
640	CUBT0008948	CUBT0008958		Abstract of Bhavnani, et al., "Toxicodynamics of Daptomycin in Patients with Bacteremia and/or Endocarditis"	I, H
641	CUBT0008959	CUBT0008960	2005	Echevarria et al., "Severe myopathy and possible hepatotoxicity related to daptomycin," J. Antimicrobial Chemotherapy	I
642	CUBT0008961	CUBT0008962	3/2/2005	Hot News Summary re Echevarria et al., "Severe myopathy and possible hepatotoxicity related to daptomycin"	I
643	CUBT0008963	CUBT0009026		[redacted]	I
644	CUBT0009027	CUBT0009053	3/6/2006	[redacted]	I, C, A-D - DRAFT
645	CUBT0009149	CUBT0009151		[redacted]	H, A-A
646	CUBT0009249	CUBT0009249	12/20/1983	[redacted]	H, A-A, I
647	CUBT0009250	CUBT0009251	5/8/1985	[redacted]	H, A-A, I
648	CUBT0009252	CUBT0009254	4/30/1985	[redacted]	H, A-A, I
649	CUBT0009256	CUBT0009259		[redacted] s"	H, A-A, P
650	CUBT0009260	CUBT0009261		[redacted] "	H, A-A, P
651	CUBT0009824	CUBT0009838	6/7/1990	[redacted]	H, A-A
652	CUBT0009277	CUBT0009284	6/29/2010	[redacted]	I, NE
653	CUBT0009152	CUBT0009152	1/28/1986	[redacted]	H, A-A
654	CUB01738657	CUB01738658	4/3/1991	[redacted]	
655	CUBT0009839	CUBT0009840	8/23/1990	[redacted]	H, A-A
656	CUBT0009181	CUBT0009182	10/29/1990	[redacted]	
657	CUBT0009183	CUBT0009183	12/21/1990	[redacted]	
658	CUBT0009184	CUBT0009242	2/27/1989	[redacted]	

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
659	CUBT0009243	CUBT0009248	4/18/2008	Jarvis, "An Uphill Battle; With short lives and uncertain profits, antibiotics are a unique development challenge for drug companies," Chemical & Engineering News	I, H
660	CUBT0009285	CUBT0009286	3/4/1997	[redacted]	I
661	CUBT0009331	CUBT0009364	7/16/1997	[redacted]	I, H, R - COMPILATION OF MULTIPLE DOCUMENTS
662	CUBT0009495	CUBT0009495	4/13/1998	Fax[redacted]	I, H
663	CUBT0009287	CUBT0009287	4/23/1998	[redacted]	I, X
664	CUBT0009288	CUBT0009288	8/5/1998	[redacted]	I
665	CUBT0009289	CUBT0009293	1/21/1999	[redacted]	I, H
666	CUBT0009294	CUBT0009294	6/8/2001	[redacted]	I, X
667	CUBT0009295	CUBT0009295		[redacted]	I, A-D - DRAFT
668	CUBT0009315	CUBT0009315	10/8/1998	[redacted]	I, H
669	CUBT0009496	CUBT0009502	5/27/1987	[redacted]	C
670	CUBT0009618	CUBT0009634	10/25/1990	[redacted]	C
671	CUBT0009664	CUBT0009701	7/31/1987	[redacted]	C

Def. Hospira's Supplemental Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
672	N/A	N/A		Cubist Patent Protection Guide: Cubicin	I
673	N/A	N/A	8/6/2001	Provisional Application 60/310,385	I

EXHIBIT 6

EXHIBIT 6

WITNESSES THAT CUBIST INTENDS TO CALL IN PERSON OR BY SWORN TESTIMONY AT TRIAL

Cubist expects to call the following witnesses in person in its case-in-chief or in rebuttal during the upcoming trial. To the extent permitted by the Federal Rules of Evidence, Cubist also reserves the right to introduce the prior sworn testimony (e.g., deposition testimony) of any witness named below.

1. Dr. Ernst R. Berndt
   Alfred P. Sloan School of Management
   Massachusetts Institute of Technology
   100 Main Street, E62-518
   Cambridge, MA 02142

2. Dr. William Gerwick
   Center for Marine Biotechnology and Biomedicine
   Scripps Institution of Oceanography
   University of California, San Diego
   9500 Gilman Drive, MC 0212
   La Jolla, CA 92093

3. Dr. Bernard J. Guglielmo
   University of California, San Francisco
   School of Pharmacy
   C-152, Box 0622
   521 Parnassus Avenue
   San Francisco, CA 94143

4. Dr. Thomas Kelleher
   Director, Global Operations
   Amgen, Inc.
   One Amgen Center Drive
   Thousand Oaks, CA 91320

5. Dr. Allan S. Myerson
   Department of Chemical Engineering
   Massachusetts Institute of Technology
   77 Massachusetts Avenue, Room 66-568
   Cambridge, MA 02139

Cubist may also call the following witnesses in person in its case-in-chief or in rebuttal during the upcoming trial. To the extent permitted by the Federal Rules of Evidence, Cubist also reserves the right to introduce the prior sworn testimony (e.g., deposition testimony) of any witness named below.

1. Dr. Barry I. Eisenstein
   Cubist Pharmaceuticals, Inc.
   65 Hayden Avenue
   Lexington, MA 02421

2. Dr. Jan-Ji Lai
   Cubist Pharmaceuticals, Inc.
   65 Hayden Avenue
   Lexington, MA 02421

3. Dr. Frederick B. Oleson, Jr.
   Cubist Pharmaceuticals, Inc.
   65 Hayden Avenue
   Lexington, MA 02421

4. Dr. James Woodworth
   [redacted]

5. Dr. Michael Zeckel
   Eli Lilly and Company
   Lilly Corporate Center
   Indianapolis, IN 46285

Cubist intends to introduce prior sworn testimony (e.g., deposition testimony) for the witnesses named below.

1. Patrick J. Baker
   [redacted]

2. Dr. Richard H. Baltz
   [redacted]

3. Dr. Manuel Debono
   [redacted]

4. Dr. Robert C. Moellering, Jr.
Department of Medicine
Beth Israel Deaconess Medical Center
110 Francis Street, Suite 6A
Boston, MA 02215

5. Mr. Stuart Murray
Cubist Pharmaceuticals, Inc.
65 Hayden Avenue
Lexington, Massachusetts 02421

6. Ms. Jin Yu
[redacted]

7. Ms. Lisa Zboril
[redacted]

8. Mr. Wei Zhou
[redacted]

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

CUBIST PHARMACEUTICALS, INC., Plaintiff, v. HOSPIRA, INC., Defendant.	Civil Action No. 12-367-GMS (CONSOLIDATED)

HOSPIRA'S OBJECTIONS TO CUBIST'S WITNESS LIST

Defendant Hospira, Inc. ("Hospira") reserves its rights to raise the following objections at trial:

1. Hospira objects to the extent that Cubist's witness list calls for live testimony from any person not within the Court's subpoena power under Fed. R. Civ. P. 45 who will not appear voluntarily.

2. Hospira objects to the extent that the calling of Drs. Gerwick and Myerson will result in duplicative, cumulative testimony regarding the non-obviousness and anticipation of the '238 and '342 patents. Cubist has represented that Dr. Gerwick will testify regarding the chemical properties of daptomycin, whereas Dr. Myerson will testify regarding commercial purification process design. Given that none of the asserted claims of the '238 and '342 patents include claim limitations directed at a commercial process, "commercial purification process design" is irrelevant.

3. Hospira reserves the right to object to each witness if he/she is called at trial.

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

CUBIST PHARMACEUTICALS, INC., Plaintiff, v. HOSPIRA, INC., Defendant.	Civil Action No. 12-367-GMS (CONSOLIDATED)

HOSPIRA'S WITNESS LIST

Subject to the availability of each witness at the time of trial, Hospira intends to call the following witnesses in person:

1. **Simon Baker, Ph.D.**
   16 The Edge Business Centre,
   Humber Road, London NW2 6EW

2. **Pranatharthi Chandrasekar, M.D.**
   Division of Infectious Diseases
   Department of Internal Medicine
   Harper University Hospital
   3990 John R, 5 Hudson, Room 5911
   Detroit, MI 48201

3. **Steven C. Ebert, Pharm.D.**
   Meriter Hospital
   Department of Pharmacy
   202 S. Park St.
   Madison, WI 53715

4. **Bruce Ganem, Ph.D.**
   Baker Laboratory
   Cornell University
   Ithaca, NY 14853

5. **Gordon C. Rausser, Ph.D.**
   OnPoint Analytics, Inc.
   2000 Powell Street, Suite 860
   Emeryville, CA 94608

Subject to the availability of each witness at the time of trial, Hospira may call the following witnesses in person:

1. **Timothy Douros, J.D.**
   [redacted]

2. **Cubist Pharmaceuticals, Inc. Custodian of Records**

Hospira also may call the following witnesses in person at trial, if necessary:

1. **Allan Myerson, Ph.D.**
   [redacted]

The parties have agreed that Hospira may cross-examine this witness without limitation to the scope of the direct examination. If Cubist does not call this witness during its case-in-chief, Hospira reserves the right to call him in its rebuttal case.

To the extent permitted by the Federal Rules of Evidence and the Federal Rules of Civil Procedure, Hospira also reserves the following rights:

(a) to introduce the prior sworn testimony (e.g., deposition testimony) of any witness named above in lieu of in-person examination;

(b) to introduce any deposition testimony designated by the parties as included in this pretrial order;

(c) to call or introduce prior testimony of any person appearing on Cubist's witness list;

(d) to call or introduce prior testimony of any person necessary to provide rebuttal testimony.

CUBIST'S OBJECTIONS TO HOSPIRA'S WITNESS LIST

Cubist Pharmaceuticals Inc. ("Cubist") hereby objects to Hospira's Witness List as follows:

1. Cubist objects to Hospira's listing of any witness that it does not reasonably believe will attend the trial voluntarily and neither resides in Delaware nor resides, is employed, or regularly transacts business in person within 100 miles of the Court. Fed. R. Civ. P. 45(d)(1). In particular, Cubist objects to the listing of non-party Mr. Paul Lynch on Hospira's list of witnesses that it "may call" in person.

2. Cubist objects to Hospira's listing of broad categories of potential in-person witnesses, including "any person designated by Cubist in its initial disclosures as a person with knowledge" and "any person, including a document custodian, for the purposes of authenticating or providing foundation for any document that appears on the exhibit list." Cubist requests that Hospira provide a witness list containing a reasonable number of specifically identified trial witnesses.

3. Cubist objects to Hospira's purported reservation of rights to introduce "prior sworn testimony (e.g., deposition testimony)" from any witness named on its witness list, any person appearing on Cubist's witness list, any person designated by Cubist in its initial disclosures as a person with knowledge, unnamed document custodians, and "any person necessary to provide rebuttal testimony." Cubist objects to the introduction of any deposition testimony (other than for purposes of impeachment) not properly designated pursuant to the parties' agreement on deposition designations and included in this pretrial order.

EXHIBIT 8

EXHIBIT 8

CUBIST'S EXPERT WITNESS LIST WITH HOSPIRA'S OBJECTIONS

Subject to the availability of each witness at the time of trial and any future stipulations entered into by the parties, Plaintiff Cubist Pharmaceuticals, Inc. ("Cubist") will call the following expert witnesses in person. In addition to identifying the expert witnesses Cubist expects to call at trial, Cubist has included a brief statement about each expert's qualifications and expected testimony, and defendant Hospira, Inc.'s ("Hospira") objections thereto.[1]

1. Ernst Berndt

Background/Qualifications:

Ernst Berndt, Ph.D., is a health economist and Professor of Applied Economics in the Sloan School of Management at the Massachusetts Institute of Technology. Between 2004 and 2013, Prof. Berndt also served as Co-Director of the Biomedical Enterprise Program, a joint degree-granting program at the Harvard–MIT Division of Health Sciences and Technology and the MIT Sloan School of Management.

Expected Testimony:

Cubicin® is a commercial success and there is a nexus between the drug's success and the claimed inventions. The dosing regimen claimed in U.S. Patents Nos. 6,468,967 ("the '967 patent") and 6,852,689 ("the '689 patent") has been approved by the FDA and directly contributes to the safe and effective administration of Cubicin®. The claimed dosing regimen enables physicians to prescribe Cubicin® at doses sufficient to treat deep-seated, serious, and complicated infections, and thus contributes to the product's commercial success. The convenience of once-daily dosing also drives Cubicin®'s high market share in the out-patient setting.

[1] Cubist's experts' opinions are more fully set forth in their respective expert reports.

The highly purified daptomycin compositions described in U.S. Patents Nos. 8,058,238 ("the '238 patent"), and 8,129,342 ("the '342 patent") also contribute to the commercial success of Cubicin®. The commercial product Cubicin® embodies the claims of the '238 and '342 patents. The claimed inventions reduce the amount of unsafe impurities called endotoxins found in Cubicin® and enable Cubicin® to be manufactured on a commercial scale. There is a clear nexus between sales of Cubicin® and Cubist's ability to manufacture highly purified daptomycin with lower levels of endotoxins in a cost-effective manner.

Furthermore, consideration of the factors that drive sales of prescription drugs shows that the commercial success of Cubicin® is related to the patented inventions.

2. William Gerwick

Background/Qualifications:

William Gerwick, Ph.D., an expert in the field of natural products, is a Distinguished Professor of Pharmaceutical Sciences at Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego, and a Distinguished Professor of Oceanography at Scripps Institution of Oceanography at the University of California, San Diego. Prof. Gerwick's research has focused on the discovery, isolation, and characterization of natural products, including the purification of lipopeptides.

Expected Testimony:

U.S. Patent No. 4,874,843 ("the '843 patent") does not anticipate asserted claims 93, 183, and 185 of the '238 patent. The products disclosed and claimed in the '238 patent and the '342 patent—daptomycin compositions of certain overall purities and impurity profiles, produced by process steps that reduce the amounts of certain impurities—are fundamentally different from the daptomycin compositions that existed in the prior art.

The asserted claims of the ’238 and ’342 patents are not obvious over the prior art. The prior art did not disclose or suggest the high-purity daptomycin compositions of the asserted claims. In addition, the process steps recited for obtaining the claimed higher purity daptomycin compositions would not have been obvious, and it would not have been possible to predict that one should apply them to daptomycin or that they would work to purify daptomycin. Secondary considerations of non-obviousness, including unmet need, failure of others, and unexpected results, also demonstrate the non-obviousness of the asserted claims of the ’238 and ’342 patents.

The asserted claims of the ’238 and ’342 patents are supported by sufficient written description.

The asserted claims of U.S. Patent No. RE39,071 (“the RE’071 patent”) are supported by sufficient written description. The Certificate of Correction was proper because it corrected a mistake of minor character in the RE’071 patent.

3. Bernard Guglielmo

Background/Qualifications:

Bernard J. Guglielmo, Pharm.D., an expert in the safe and effective use of antibiotics in the treatment of infectious diseases, is the Dean of the School of Pharmacy at the University of California, San Francisco (“UCSF”). He is also the Troy C. Daniels Distinguished Professor in Pharmaceutical Sciences and a Professor of Clinical Pharmacy at UCSF. Prof. Guglielmo is a Clinical Pharmacist in Infectious Diseases and an attending pharmacist at the UCSF Medical Center, as well as the Associate Director for the Department of Pharmaceutical Services at UCSF Medical Center. His research is focused on the safe, effective use of antimicrobials.

Expected Testimony:

U.S. Patent No. 5,912,226 and Woodworth et al., *Single-Dose Pharmacokinetics and Antibacterial Activity of Daptomycin, a New Lipopeptide Antibiotic, in Healthy Volunteers*, Antimicrobial Agents & Chemotherapy, Vol. 36, No. 2, 318-325 (1992), do not anticipate the asserted claims of the ’967 patent because neither discloses each and every element of the asserted claims, either expressly or inherently. These prior art references are also not enabling.

The ’967 and ’689 patents are not obvious. Nothing in the prior art taught or suggested that the claimed dosing regimens for daptomycin would minimize skeletal muscle toxicity. Nothing in the prior art taught or suggested that once-daily dosing of daptomycin could effectively treat a bacterial infection in a human patient when administered at a dose that would also minimize skeletal muscle toxicity. Secondary considerations of non-obviousness, including unmet need, failure of others, unexpected results, and praise following initial skepticism, also demonstrate the non-obviousness of the asserted claims of the ’967 and ’689 patents.

The asserted claims of the ’967 and ’689 patents are supported by sufficient written description.

4. Allan Myerson

Background/Qualifications:

Allan S. Myerson, Ph.D., an expert in both small-scale and commercial-scale separation and purification methods, is Professor of the Practice of Chemical Engineering in the Department of Chemical Engineering at the Massachusetts Institute of Technology and a co-principal investigator at the Novartis–MIT Center for Continuous Manufacturing. His research is focused on separation and purification methods, crystallization, pharmaceutical manufacturing, and novel methods of pharmaceutical formulation.

Expected Testimony:

The claimed inventions of the ’238 and ’342 patents represented significant improvements over the prior art, both in terms of the quality of the product produced and the ability to produce the product with good yield. As a consequence, the claimed inventions helped to satisfy a long-felt need by enabling commercial-scale production of highly pure daptomycin compositions. It would not have been obvious or predictable to obtain an effective and efficient purification technique to produce daptomycin compositions as claimed.

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

CUBIST PHARMACEUTICALS, INC.,	)	
Plaintiff,	)	
v.	)	Civil Action No. 12-367-GMS (CONSOLIDATED)
HOSPIRA, INC.,	)	
Defendant.	)	

HOSPIRA'S OBJECTIONS TO QUALIFICATIONS AND EXPECTED SUBJECT MATTER OF CUBIST'S EXPERT WITNESSES

1. Dr. Ernst Berndt

Hospira objects to the qualifications of Dr. Ernst R. Berndt with respect to any opinion or testimony directed at: (1) the alleged inventions claimed in any of the asserted patents, and (2) the question of whether Plaintiff has demonstrated a nexus between asserted claims of the '071 Patent, the '967 Patent, the '689 Patent, the '238 Patent, and/or the '342 Patents and the alleged commercial success of Cubicin®.

Hospira objects to Dr. Berndt's qualifications on these topics because Dr. Berndt admits that he does not know whether any court had construed any of the terms of the asserted claims of the patents and further admits that he had not reviewed any claim construction order. Accordingly, Dr. Berndt cannot opine on the alleged inventions claimed in any of the asserted patents. Moreover, Dr. Berndt cannot make the requisite connection between the alleged invention or inventions in the asserted claims in the patents and any alleged commercial success of Cubicin®.

EXHIBIT 9

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

CUBIST PHARMACEUTICALS, INC., Plaintiff, v. HOSPIRA, INC., Defendant.	Civil Action No. 12-367-GMS (CONSOLIDATED)

QUALIFICATIONS AND EXPECTED SUBJECT MATTER OF HOSPIRA'S EXPERT WITNESSES

1. **Simon Baker, Ph.D.**

Background/Qualifications

Dr. Simon Baker is the Director of Global Research & Development for Bioline Reagants, Ltd., where he bears responsibility for new product development and project management related to enzymes and buffers associated with DNA and RNA technologies. He received a Ph.D. in Biological Sciences from the University of Warwick in Coventry, England in 1991, where his research focused primarily on microbial physiology. After obtaining his graduate degree, he was awarded a Royal Society European Fellowship, which he served at the University of Groningen in Haren, Netherlands. He was then named a SERC Postdoctoral Research Assistant and BBSRC Postdoctoral Research Assistant at the University of Oxford in London, England.

In 2000, Dr. Baker became a lecturer in Microbiology at Birkbeck College, University of London, School of Biology and Chemistry. During the same time, he served as a Research

Manager in the Research and Development Department at ABgene, a small DNA technology company. He also served as a research consultant for Thermo Fisher, Genomics Group in Surrey, United Kingdom, while serving an appointment as Senior Lecturer in Biotechnology at the School of Life Sciences, Microbiology Section, at Oxford Brookes University in Oxford, United Kingdom.

Dr. Baker currently serves on the editorial board of directors for *Biotechnology Letters* and is a member of the Biochemical Society. Throughout his career, he received several grants, including funding for a three-year research project relating to a process for producing surfactin—a lipopeptide biosurfactant. He also has worked in a long-term collaboration with Professor Richard Darton, a leading scientist whose work focuses on the separation of peptides from liquids.

Dr. Baker has published two books and a book chapter relating to microbiology, as well as numerous papers relating to lipopeptide biosurfactants, including methods of purifying biosurfactants. He is also a named inventor on three patents covering technology relating to modified microorganisms with inactivated lactate dehydrogenase genes.

Dr. Baker's *curriculum vitae* is incorporated herein by reference.

Expected Testimony

As set forth in his expert reports, which are incorporated by reference, Dr. Baker will testify that at least one product of the prior art '843 patent, *i.e.*, about 93% pure daptomycin relative to the certain specified impurities, anticipates certain claims of the '238 patent—and to the extent not claimed in the '843 patent, is dedicated to the public. Dr. Baker will also testify about the qualifications of a person of ordinary skill in the art for the '238 and '342 patents. In addition, Dr. Baker will testify that obtaining so-called higher purity compositions covered by

the ‘238 and ‘342 patents would be obvious to a person of skill in the art because the claimed product was an obvious extension of the ‘843 patent obtained by methods already well known by 2000. Moreover, to the extent the Court considers the process limitations in assessing the validity of the asserted claims, they too would be obvious to a person of ordinary skill in the art.

Dr. Baker will testify that the ‘238 and ‘342 patents are also invalid for lack of written description because a person of ordinary skill in the art would have understood the term “daptomycin” to mean L-asparagine daptomycin, not D-asparagine daptomycin.

Dr. Baker will further testify that U.S. Patent No. 4,537,717 inherently anticipates the ’071 patent, and that the ‘071 patent is an obviousness-type double patenting of U.S. Patent No. 4,537,717.

2. Pranatharthi H. Chandrasekar, M.D.

Background/Qualifications

Dr. Chandrasekar is a board-certified physician practicing at Harper University Hospital in Detroit, Michigan. He specializes in internal medicine and in the treatment of infectious disease, with a focus on antibiotic resistance. In over 25 years of medical practice, Dr. Chandrasekar has had extensive experience treating patients with bacterial infections and in administering antibiotics including daptomycin and vancomycin. Dr. Chandrasekar is particularly experienced in the treatment of MRSA infections, which are prevalent in Detroit, particularly in the intravenous drug user population.

In addition to his clinical work, Dr. Chandrasekar is a Professor in the Department of Internal Medicine at Wayne State University. He has lectured extensively on topics including fundamental principles of infectious diseases, and the management of infections. He has also published extensively, having written over 150 peer-reviewed publications and over 200

published abstracts on topics which include the clinical applicability of various antimicrobials. He has also authored 13 book chapters, various educational materials regarding the treatment and management of infections, and numerous book reviews and case reports.

Dr. Chandrasekar holds several other leadership roles in his field. He is Chief of the Infectious Diseases division of Karmanos Cancer Institute, and the Program Director for the Infectious Diseases Fellowship at Wayne State University. He is also on the Chief of the Antibiotic subcommittee within the Pharmacy and Therapeutics Committee at the Karmanos Cancer Institute. Further, he is an editor, editorial board member, and/or journal reviewer of several major publications including the British Journal of Antimicrobial Chemotherapy, GERMS, The Scientific World Journal, and the Open Antimicrobial Agent Journal.

Expected Testimony

As set forth in his expert report, which is incorporated by reference, Dr. Chandrasekar will testify that there is no nexus between any alleged secondary considerations of long-felt need, skepticism, and/or praise, and the inventions claimed in any of the asserted patents. To the extent there is a nexus between any secondary considerations of long-felt need, skepticism, and/or praise and the patented inventions, such consideration is not sufficiently significant to render the patented inventions non-obvious. Dr. Chandrasekhar will also testify that there are also no secondary considerations relevant to administering daptomycin once every 48 hours as claimed in the ‘689 patent.

3. **Steven C. Ebert, Pharm.D.**

Background/Qualifications

Dr. Ebert is a Clinical Professor of Pharmacy at the University of Wisconsin and Clinical Manager in Infectious Diseases at the Department of Pharmacy at Meriter Hospital in

Wisconsin. He is a licensed pharmacist and also a Fellow of The American College of Clinical Pharmacy and The Infectious Diseases Society of America.

For over 30 years, Dr. Ebert has taught the fundamental principles of infectious diseases, pharmacotherapy, antibiotic pharmacology, and clinical pharmacokinetics to over 3000 graduate and nursing students. His research has focused on antiinfective pharmacology in a variety of animal models. Among other things, he has researched the pharmacokinetic disposition of daptomycin in animal models. Dr. Ebert has also published extensively in his area of expertise, authoring over 50 articles, abstracts, and book chapters, on antimicrobial pharmacokinetics and pharmacodynamics,. He is also a reviewer for several peer-reviewed journals including the American Journal of Health-System Pharmacy, Antimicrobials Agents and Chemotherapy, Pharmacotherapy, and Annals of Pharmacotherapy.

At Meriter Hospital, Dr. Ebert manages the treatment and management of infectious disease and advises physicians on selection of therapies. He also designs antibiotic dosing regimens for use by physicians in the treatment of infection. He has extensive experience with the treatment of patients having MRSA infections, including the use of vancomycin and daptomycin in the treatment of such patients. Dr. Ebert has also chaired several groups within Meriter Hospital, including the Clinical Practice Group and the Clinical Advisory Team. His responsibilities in these positions included developing and implementing clinical pharmacy activities within the hospital.

Beyond the hospital, Dr. Ebert has also been involved in the development of drug dosing regimens prior to FDA approval. In particular, he was a member of an internal advisory board that provided recommendations to the NDA sponsor of levofloxacin on how to adjust the dosing when administering the drug to a renally impaired patient.

Dr. Ebert's panel and committee service further demonstrate his expertise. For instance, he has served on several committees including the USFDA's Anti-Infective Drug Advisory Committee and the Pediatric Advisory Committee. In addition, he has served as President of the Society of Infectious Diseases Pharmacists, as Chair of the Executive Council for the Wisconsin Antimicrobial Resistance Network, and as a Member of the Board of Directors of the Pharmacy Society of Wisconsin. He has also served on numerous panels on antimicrobial toxicity, antimicrobial pharmacodynamics, and clinical pharmacy. In 1998, Dr. Ebert received the award of "Pharmacist of the Year" from the Pharmacy Society of America and received the Research Award from the Wisconsin Society of Hospital Pharmacists.

Expected Testimony

As set forth in his expert reports, which are incorporated by reference, the subject matter of Dr. Ebert's testimony will include the following: the state of the art in the late 1990s relating to antibiotic dosing regimens including the pharmacokinetic and pharmacodynamic considerations that a person of ordinary skill in the art would consider relevant to developing a dosing regimen that maximizes the antibiotic's beneficial or therapeutic effect, while minimizing its negative or toxic effects; the qualifications and knowledge of a person of ordinary skill in the art as of 1998; whether a person of ordinary skill in the art would have believed that, as of 1998, the inventors of the '967 and '689 patents were in possession of the claimed methods of administering daptomycin having an asparagine residue that is in the D-configuration; the reasons why the asserted claims of the '967 patent are invalid for anticipation; the reasons why the asserted claims of the '967 and '689 patents are invalid for obviousness over the prior art; the reasons why there are no unexpected results sufficient to overcome obviousness of the asserted

claims of the ‘967 and ‘689 patents; and the reasons why the asserted claims of the ‘967 and ‘689 patents are invalid for lack of written description.

4. **Bruce Ganem, Ph.D.**

Background/Qualifications

Dr. Ganem is the Franz and Elisabeth Roessler Professor of Chemistry in the Department of Chemistry and Chemical Biology at Cornell University in Ithaca, New York. His principal field of expertise is synthetic organic chemistry, which includes the development of synthetic methodology and the design and preparation of natural products and other bioactive compounds. Dr. Ganem received a Bachelor’s degree in chemistry from Harvard College in 1969, and a Ph.D. in organic chemistry from Columbia University in 1972. He then moved to Stanford University as a postdoctoral fellow during 1973-74, and subsequently accepted a faculty post at Cornell in 1974. He served as Chairman of the Department of Chemistry from 1993 through 1997, and again in 2001.

His research in organic chemistry focuses on a range of problems in organic synthesis, synthetic methodology, and drug design, including the development of new synthetic methods, applications of synthetic organic chemistry to the preparation of complex organic compounds, and the discovery and development of small molecule therapeutics. During the past 39 years at Cornell, Dr. Ganem’s research group and he have published more than 250 papers in peer-reviewed journals. Under his direction, 55 graduate students have completed their Ph.D. degrees, and more than 70 postdoctoral associates and visiting scientists have carried out advanced research in his laboratories. His research has led to the filing of several U.S. patent applications on which he is listed as an inventor or co-inventor, several of which have issued as patents.

During the past 39 years, Dr. Ganem has taught the fundamental principles of organic chemistry, organic reaction mechanisms, stereochemistry, and organic synthesis as well as experimental laboratory techniques in organic chemistry to more than 12,000 undergraduate students pursuing degrees in medicine, dentistry, food science, nutrition, agriculture, biology, physics, engineering, and chemistry.

Dr. Ganem was appointed as Executive Editor of *Tetrahedron Letters*, an international journal for the rapid publication of organic chemistry research, and held that position from 1988 through 2011. He also served as the Chairman of the Board of Executive Editors for Tetrahedron Publications, which comprises five scientific journals (including *Tetrahedron Letters*) published by Elsevier, between the years 2004 and 2006. Dr. Ganem additionally served on the editorial advisory boards of several other peer-reviewed journals, including the *Journal of Organic Chemistry* and the *Canadian Journal of Chemistry*.

Dr. Ganem has received several awards throughout his career, including the Cope Scholar Award from the American Chemical Society in 1996, the Catalyst Award from the Chemical Manufacturers Association in 1999, the Presidential Green Chemistry Challenge Award in 2007, and the American Chemical Society Award for Creative Invention, also in 2007. In 2012, Dr. Ganem received the American Chemical Society's Esselen Award for Chemistry in the Public Interest. He has also been named a Weiss Presidential Fellow by the Trustees of Cornell University.

Dr. Ganem has also served as a consultant to numerous pharmaceutical and biotechnology firms, and has co-founded or helped launch several startup companies. Dr. Ganem's *curriculum vitae* is incorporated herein by reference, and in particular, reflects the complete list of papers and book chapters Dr. Ganem has co-authored.

Expected Testimony

As set forth in his expert reports, which are incorporated by reference, Dr. Ganem will offer testimony relating to the invalidity of the Certificate of Correction to the ’071 patent because the Certificate of Correction did not correct an “error of minor character,” at least because it broadened the claims of the ’071 patent. He will further testify that, if the Certificate of Correction is determined to be valid, then the asserted claims of the RE’071 are invalid because the specification does not support them (i.e., it would not lead a person of ordinary skill at the time of the patent’s filing to believe that Formula 3 had a D-asparagine configuration).

5. **Allan Myerson, Ph.D.**

Background/Qualifications

Dr. Myerson is currently Professor of the Practice of Chemical Engineering at the Massachusetts Institute of Technology in Cambridge, Massachusetts, who has conducted research for over 30 years in the separation and purification methods used in the chemical, pharmaceutical, and food industries.

Dr. Myerson obtained a Bachelor of Science in chemical engineering in May 1973 from Columbia University in New York, New York. Thereafter, he obtained Master’s and Ph.D. degrees in chemical engineering from the University of Virginia in Charlottesville, Virginia in January 1975 and 1977, respectively. He is a registered Professional Engineer in New York and Ohio.

In January 1977, Dr. Myerson began his academic career as an Assistant Professor of Chemical Engineering at the University of Dayton, where he worked until August 1979. From September 1979 to December 1984, he was a faculty member at the Georgia Institute of Technology in Atlanta, serving first as an Assistant Professor of Chemical Engineering and

subsequently as an Associate Professor. In January 1985, Dr. Myerson joined the faculty of the Polytechnic University (now known as Polytechnic Institute of New York University) in Brooklyn, New York. While there, he served in various positions, including as Joseph and Violet J. Jacobs Professor of Chemical Engineering, Head of the Department of Chemical Engineering, Dean of the School of Chemical and Materials Science, and Vice Provost for Research and Graduate Studies. In January 2000, Dr. Myerson moved to the Illinois Institute of Technology in Chicago ("IIT"), where he began as Professor of Chemical Engineering and Dean of the Armour College of Engineering and Science. He remained in that position until January 2003, when he became the Philip Danforth Armour Professor of Engineering. Between 2003 and 2008, he was also Provost and Senior Vice President at IIT. He moved from IIT to his current position at MIT in August 2010.

Dr. Myerson's current research focuses on separation and purification methods, crystallization, pharmaceutical manufacturing, and novel methods of pharmaceutical formulation. He serves as a co-principal investigator at the Novartis-MIT Center for Continuous Manufacturing, which is a 10-year, $85 million research collaboration aimed at improving pharmaceutical manufacturing. The goal of the Center is to develop new technologies to improve pharmaceutical manufacturing and replace current batch manufacturing systems with continuous manufacturing.

Over the course of his career, Dr. Myerson has supervised the Ph.D. dissertations of approximately 38 students and the research of approximately 20 post-doctoral research associates.

Dr. Myerson has presented the results of his research, including on separation and purification processes, at numerous national and international meetings and has published

approximately 190 papers in refereed scientific journals. He also is an inventor on 37 U.S. patents. Many of his papers and patents pertain to separation and purification processes.

In addition to his academic work, he has consulted for approximately 100 companies worldwide on issues related to separation and purification processes, including process development and troubleshooting of existing processes. He has also edited five books in the area of separation and purification processes, including the Handbook of Industrial Crystallization, 2nd edition (Butterworth, 2001), and Crystallization as a Separation Process (ACS Books, 1990). He is also the Associate Editor of *Crystal Growth and Design*, a journal published by the American Chemical Society.

Dr. Myerson has received several awards and honors for his research accomplishments. These include the American Chemical Society Division of Industrial and Engineering Chemistry Fellow Award in 2010, the American Chemical Society Award in Separation Science and Technology in 2008, the Louise W. Busse Pharmacy Lectures at the University of Wisconsin College of Pharmacy in 2006.

Dr. Myerson's *curriculum vitae* is incorporated herein by reference.

Expected Testimony

Though retained by Cubist, Dr. Myerson is expected to testify that the methods, processes, and techniques for separating and purifying daptomycin were used prior to 2000. He will likely further testify that performing the process taught in the prior art '843 patent can result in a composition comprising about 93% pure daptomycin relative to certain specified impurities. Dr. Myerson will also likely testify that a person of ordinary skill in the art would review the bioseparations literature to determine how to separate daptomycin, including literature on

separating similar molecules (such as surfactin literature). His testimony will likely relate to the anticipation of the '238 patent, as well as the obviousness of the '238 and '342 patents.

6. **Gordon C. Rausser, Ph.D.**

Background/Qualifications

Gordon Rausser, Ph.D. is the Robert Gordon Sproul Distinguished Professor at the University of California, Berkeley where he teaches both Economics and Statistics at the graduate and undergraduate levels. Dr. Rausser received his Ph.D. with Highest Honors from the University of California at Davis in 1971, and in 1973 was awarded a Postdoctoral Fellowship in Economics and Statistics at the University of Chicago. Dr. Rausser is an elected Fellow of the American Association for the Advancement of Science (1994), the American Statistical Association (1991), and the Agricultural & Applied Economics Association (1990). In 1987, Dr. Rausser was a Fulbright Scholar in Australia.

In his academic career, he has held positions teaching economics and statistics at many universities including the University of Chicago, Harvard University, the University of California at Berkeley, University of Illinois, Iowa State University, the University of California at Davis, and Hebrew University. He served as Dean of the College of Natural Resources at the University of California, Berkeley from 1994–2000, and has three times been selected by his colleagues as Chair of his academic department. Dr. Rausser has published extensively in academic and professional journals on the application of statistical methods, market dynamics, industrial organization, environmental and resource economics, public policy, and futures and options. During his academic career, he has published more than 250 articles, books and book chapters. In addition, he has written more than 100 commissioned papers, governmental reports,

and working papers. Dr. Rausser has won 16 national awards and honors for his teaching and research.

Dr. Rausser is the Editor of the Annual Review of Resource Economics. He is also a past Associate Editor of the Journal of the American Statistical Association and the Journal of Economic Dynamics and Control, and a past Editor of the American Journal of Agricultural Economics. From 1986 to 1987, he was Senior Economist at the President's Council of Economic Advisors with responsibility for finance, trade, and agriculture. While on leave from the University of California at Berkeley, he served as the Chief Economist at the Agency for International Development in Washington, D.C. from 1988 to 1990.

In addition to his academic experience, he has served as an economic consultant to government agencies and private clients for more than thirty years. His work has focused on the application of economics and finance to complex legal and public policy disputes. He has extensive consulting experience in issues associated with economic damage determination, economic feasibility studies, unfair competition, market analysis, risk valuation, and statistical and econometric modeling. He often provides expert testimony in matters involving pharmaceutical products, patent infringement, commercial success, new product introduction, and damages flowing from delayed entry, or anticompetitive barriers to market entry. These engagements have included analyses of pharmaceutical pricing structures and practices, factors influencing sales success, and competition between pharmaceutical products. Dr. Rausser's work has required him to examine the economic operation of virtually every major class of drugs, including analgesics, anti-infectives, antidepressants, anti-hypertensives, behavioral medications, cancer therapies, anti-secretory drugs, diabetes treatments, hormone replacement therapies and others.

Dr. Rausser's *curriculum vitae* is incorporated herein by reference.

Expected Testimony

As set forth in his expert report, which is incorporated by reference, Dr. Rausser will testify as to whether Plaintiff has demonstrated that any evidence of the alleged commercial success of Cubicin® is probative of the non-obviousness of the claims of each asserted patent. More specifically, Dr. Rausser will testify that (1) Dr. Berndt has overstated Cubicin's commercial success, and (2) Cubicin's sales are not an indicator of nonobviousness because there is no demonstrated nexus between those sales and any of the claimed inventions.

Dr. Rausser is also expected to testify that Lilly's termination of daptomycin development is not an indication of nonobviousness because Lilly terminated development for economic reasons.

CUBIST'S OBJECTIONS TO HOSPIRA'S EXPERT WITNESS QUALIFICATIONS

Plaintiff Cubist Pharmaceuticals, Inc. ("Cubist") hereby submits its objections to defendant Hospira, Inc.'s ("Hospira") Expert Witness Qualifications. Cubist incorporates by reference its objections to the testimony of Dr. Rausser and Dr. Ganem set forth in Exhibit 14 of the Pretrial Order (Cubist's Statement of Evidentiary Issues It Intends to Raise), both of which should be treated as if set forth fully herein.

EXHIBIT 10

EXHIBIT 10

CUBIST'S DEPOSITION DESIGNATIONS WITH HOSPIRA'S OBJECTIONS

Objections are indicated by codes in the "Objection" column of the following list.

AA	=	Asked and answered F.R. Evid. 403, Badgering, F.R. 106
ARG	=	Argumentative, or attorney argument
BTS	=	Beyond the scope (of examination or of 30(b)(6)) F.R. Evid. 611, Fed. R.Civ. P. 30(b)(6)
F	=	No foundation or Assumes facts not in evidence F.R. Evid. 602, 901, 1002, 1003, and 1006
H	=	Hearsay if offered for the truth of the matter asserted F.R. Evid. 801, 803
I	=	Incomplete designation F.R. Evid. 106, 403 and 1003; Fed. R. Civ. P. 32(a)(4)
IH	=	Incomplete Hypothetical
L	=	Leading F.R. Evid. 611(c)
LC	=	Legal Conclusion
MIS	=	Mischaracterization of testimony or evidence
NARR	=	Narrative

NR	=	Not responsive
O	=	Unqualified Opinion F.R. Evid. 701, 702
OB	=	Attorney Objection improperly designated
P	=	Privileged F.R. Evid. 501
PK	=	Lack of personal knowledge F.R. Evid. 602
R	=	Not relevant F.R. Evid. 401, 402, and 403
S	=	Not relevant settlement agreement F.R. Evid. 408
SPEC	=	Speculation F.R. Evid. 602
V	=	Vauge or ambiguous

Cubist's objections to Hospira's counter-designations also include the following abbreviations:

(NT) Not Testimony
(FORM) Objection To Form Of Question
30(b)(6) Beyond The Scope of 30(b)(6) Deposition
(DOC) Document Speaks For Itself
(LO) Lay Opinion

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Jin Yu, Ph.D (7/30/2013)	11:18 – 12:4			
Jin Yu, Ph.D (7/30/2013)	23:14 -24:20		24:21-24	
Jin Yu, Ph.D (7/30/2013)	25:22 – 28:16			
Jin Yu, Ph.D (7/30/2013)	29:18 – 30:11			
Jin Yu, Ph.D (7/30/2013)	30:25 – 32:16	R		
Jin Yu, Ph.D (7/30/2013)	33:7 – 33:18	R	36:13-18	R
Jin Yu, Ph.D (7/30/2013)	42:12 – 43:11	R		
Jin Yu, Ph.D (7/30/2013)	44:8 – 45:6		48:25 – 49:2 49:14-18	R
Jin Yu, Ph.D (7/30/2013)	57:9 – 57:14			
Jin Yu, Ph.D (7/30/2013)	60:24 – 61:6	R		
Jin Yu, Ph.D (7/30/2013)	66:22 – 67:15	R		
Jin Yu, Ph.D (7/30/2013)	67:19 – 67:21	R		
Jin Yu, Ph.D (7/30/2013)	69:7 – 69:15	F, R, PK		
Jin Yu, Ph.D (7/30/2013)	73:2 – 73:11			
Jin Yu, Ph.D (7/30/2013)	73:20 – 74:6	H		
Jin Yu, Ph.D (7/30/2013)	74:17 – 74:22	PK, F, R		
Jin Yu, Ph.D (7/30/2013)	78:13 – 78:22	H		
Jin Yu, Ph.D (7/30/2013)	78:24 – 79:8	R, O, F		
Jin Yu, Ph.D (7/30/2013)	79:17 – 80:13	F, R, O		
Jin Yu, Ph.D (7/30/2013)	80:15 – 80:16			
Jin Yu, Ph.D (7/30/2013)	87:16 – 88:14	H, R, O	88:18-21	I, NT, R
Jin Yu, Ph.D (7/30/2013)	88:16			
Jin Yu, Ph.D (7/30/2013)	91:25 – 92:6	R, O, F	93:9-12 93:14-18	R
Jin Yu, Ph.D (7/30/2013)	93:19 – 94:18	O, R, F		
Jin Yu, Ph.D (7/30/2013)	94:21 – 95:2			
Jin Yu, Ph.D (7/30/2013)	95:4		95:6-19	R
Jin Yu, Ph.D (7/30/2013)	95:20 – 96:14	R		

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Jin Yu, Ph.D (7/30/2013)	101:15 – 103:21	R, O	105:8-17 105:25 – 106:9 106:24 – 107:5	R
Jin Yu, Ph.D (7/30/2013)	143:18 – 144:10	F, O, R		
Jin Yu, Ph.D (7/30/2013)	178:10 – 178:13			
Jin Yu, Ph.D (7/30/2013)	178:15 – 178:21	R, F		
Jin Yu, Ph.D (7/30/2013)	178:23			
Jin Yu, Ph.D (7/30/2013)	180:4 – 180:8	R		
Jin Yu, Ph.D (7/30/2013)	183:1 – 185:2	R, F		
Jin Yu, Ph.D (7/30/2013)	185:5 – 185:11	R, F		
Jin Yu, Ph.D (7/30/2013)	185:13		185:15-17 185:20-21 185:23-25 186:2-3	NR, R
Jin Yu, Ph.D (7/30/2013)	186:24 – 187:2	R, F, V	187:8-11 187:14 187:16 – 188:2 188:7-11	LC, LO, NR
Jin Yu, Ph.D (7/30/2013)	187:4	R, F, V		
Jin Yu, Ph.D (7/30/2013)	189:20 – 189:23			
Jin Yu, Ph.D (7/30/2013)	190:1 – 190:24	MIS, R, V		
Jin Yu, Ph.D (7/30/2013)	191:1 – 191:5			
Jin Yu, Ph.D (7/30/2013)	191:7– 191:16			
Wei Zhou (6/25/2013)	8:12 – 8:17			
Wei Zhou (6/25/2013)	45:18 – 46:23			
Wei Zhou (6/25/2013)	56:7 – 57:8	R, PK		
Wei Zhou (6/25/2013)	57:10– 57:20			
Wei Zhou (6/25/2013)	58:15 – 58:20	V, F, R		
Wei Zhou (6/25/2013)	58:23 – 61:20		61:21-25	
Wei Zhou (6/25/2013)	123:24 – 124:23	R, O, V	125:22 – 126:8	R, SPEC, V

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Wei Zhou (6/25/2013)	124:25 – 125:2			
Wei Zhou (6/25/2013)	145:12 – 146:15	R		
Patrick J. Baker (7/9/2013)	5:9 – 5:12			
Patrick J. Baker (7/9/2013)	8:5 – 8:10		8:13-14	
Patrick J. Baker (7/9/2013)	8:18 – 10:21			
Patrick J. Baker (7/9/2013)	11: 2 – 12:5		12:17 – 13:4	
Patrick J. Baker (7/9/2013)	13:5 – 17:1		17:13-21	I, L, MIS, R
Patrick J. Baker (7/9/2013)	20:20 – 20:24			
Patrick J. Baker (7/9/2013)	21:1 – 21:3			
Patrick J. Baker (7/9/2013)	21:5 – 21:23			
Patrick J. Baker (7/9/2013)	30:20 – 31:5			
Patrick J. Baker (7/9/2013)	31:22 – 32:9			
Patrick J. Baker (7/9/2013)	47:15 – 48:10			
Patrick J. Baker (7/9/2013)	48:12 – 48:22			
Patrick J. Baker (7/9/2013)	56:4 – 56:12		56:13-22	
Patrick J. Baker (7/9/2013)	57:3 – 57:5	O	57:9-10	R, V
Lisa Zboril (8/8/2013)	7:19 – 7:24			
Lisa Zboril (8/8/2013)	23:23 – 23:25			
Lisa Zboril (8/8/2013)	24:25 – 26:25			
Lisa Zboril (8/8/2013)	27:4 – 28:22			
Lisa Zboril (8/8/2013)	29:13 – 30:6			
Lisa Zboril (8/8/2013)	41:2 – 41:6	I, R		
Lisa Zboril (8/8/2013)	41:13 – 41:19			
Lisa Zboril (8/8/2013)	44:12 – 45:16	R, H, V, BTS		
Lisa Zboril (8/8/2013)	45:18 – 45:20			
Lisa Zboril (8/8/2013)	46:24 – 47:4	BTS, R		
Lisa Zboril (8/8/2013)	47:8 – 47:10	BTS, R	47:18-23	NR, R, V
Lisa Zboril (8/8/2013)	47:24 – 48:8	BTS, R, O, SPEC		
Lisa Zboril (8/8/2013)	48:11 – 49:13	BTS, R		

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Lisa Zboril (8/8/2013)	51:10 – 51:16			
Lisa Zboril (8/8/2013)	52:17 – 53:12	R	53:13-22	NR, R, V
Lisa Zboril (8/8/2013)	54:4 – 54:6	SPEC, BTS, R		
Lisa Zboril (8/8/2013)	54:9 – 54:15			
Lisa Zboril (8/8/2013)	58:12 – 58:17	R		
Lisa Zboril (8/8/2013)	64:2 – 64:24	R		
Lisa Zboril (8/8/2013)	65:14 – 65:24			
Lisa Zboril (8/8/2013)	67:3 – 67:14	R		
Lisa Zboril (8/8/2013)	68:17 – 68:25	R, MIS, L		
Lisa Zboril (8/8/2013)	71:9 – 71:25	R, BTS		
Lisa Zboril (8/8/2013)	72:3 – 72:7	R, BTS		
Lisa Zboril (8/8/2013)	72:18 – 73:7	R, BTS		
Lisa Zboril (8/8/2013)	73:10 – 73:14			
Lisa Zboril (8/8/2013)	73:22 -75:11	R, BTS, O, V		
Lisa Zboril (8/8/2013)	76:2 – 77:14	R		
Lisa Zboril (8/8/2013)	77:18 – 77:20	V, BTS, R		
Lisa Zboril (8/8/2013)	77:23 – 78:24	V, BTS, R		
Lisa Zboril (8/8/2013)	80:14 – 82:11	R		
Lisa Zboril (8/8/2013)	83:5 – 83:24	R		
Lisa Zboril (8/8/2013)	84:3 – 84:23	V, SPEC, BTS, R		
Lisa Zboril (8/8/2013)	86:1 – 88:1	H, R	88:2-6 88:9	NR, R
Robert C. Moellering, Jr., M.D. (11/10/2010)	5:13-5:21			
Robert C. Moellering, Jr., M.D. (11/10/2010)	9:19-11:12			
Robert C. Moellering, Jr., M.D. (11/10/2010)	12:16-14:10			
Robert C. Moellering, Jr., M.D. (11/10/2010)	15:22-15:24			

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Robert C. Moellering, Jr., M.D. (11/10/2010)	16:1-18:19	OB		
Robert C. Moellering, Jr., M.D. (11/10/2010)	18:23-19:18			
Robert C. Moellering, Jr., M.D. (11/10/2010)	22:3-23:13			
Robert C. Moellering, Jr., M.D. (11/10/2010)	29:6-29:13	R		
Robert C. Moellering, Jr., M.D. (11/10/2010)	29:15-30:6	R		
Robert C. Moellering, Jr., M.D. (11/10/2010)	30:17-31:3	R, V		
Robert C. Moellering, Jr., M.D. (11/10/2010)	31:8-31:17	OB, R, NR, SPEC		
Robert C. Moellering, Jr., M.D. (11/10/2010)	33:12-33:16	R		
Robert C. Moellering, Jr., M.D. (11/10/2010)	33:24-34:7	R, V		
Robert C. Moellering, Jr., M.D. (11/10/2010)	34:9	R, V		
Robert C. Moellering, Jr., M.D. (11/10/2010)	34:13-35:3			
Robert C. Moellering, Jr., M.D. (11/10/2010)	35:5-35:19			
Robert C. Moellering, Jr., M.D. (11/10/2010)	36:3-36:6			
Robert C. Moellering, Jr., M.D. (11/10/2010)	36:8-36:17	R, V		
Robert C. Moellering, Jr., M.D. (11/10/2010)	36:19-36:23	R, V		
Robert C. Moellering, Jr., M.D. (11/10/2010)	37:21-38:5	NR, OB, R, V	37:13-16; 37:18-20	R, V

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Robert C. Moellering, Jr., M.D. (11/10/2010)	38:14-38:25			
Robert C. Moellering, Jr., M.D. (11/10/2010)	40:23-41:18			
Robert C. Moellering, Jr., M.D. (11/10/2010)	42:23-43:2			
Robert C. Moellering, Jr., M.D. (11/10/2010)	45:4-45:14	NARR, NR, R	45:15-21	AA, V
Robert C. Moellering, Jr., M.D. (11/10/2010)	47:2-48:9			
Robert C. Moellering, Jr., M.D. (11/10/2010)	48:20-49:6	F		
Robert C. Moellering, Jr., M.D. (11/10/2010)	50:8-50:23	R	51:22-24	R, V
Robert C. Moellering, Jr., M.D. (11/10/2010)	52:16-53:10	R, NR		
Robert C. Moellering, Jr., M.D. (11/10/2010)	54:23-55:4			
Robert C. Moellering, Jr., M.D. (11/10/2010)	55:20-56:8			
Robert C. Moellering, Jr., M.D. (11/10/2010)	56:17-56:23			
Robert C. Moellering, Jr., M.D. (11/10/2010)	57:18-57:20			
Robert C. Moellering, Jr., M.D. (11/10/2010)	57:22-57:23			
Robert C. Moellering, Jr., M.D. (11/10/2010)	69:14-70:4	R	70:5-12	R, V
Robert C. Moellering, Jr., M.D. (11/10/2010)	70:13-70:17			
Robert C. Moellering, Jr., M.D. (11/10/2010)	70:25-71:14			

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Robert C. Moellering, Jr., M.D. (11/10/2010)	71:16			
Robert C. Moellering, Jr., M.D. (11/10/2010)	71:18-71:22			
Robert C. Moellering, Jr., M.D. (11/10/2010)	72:11-72:13	H, NARR, NR, O, PK, SPEC, V	76:2-4; 76:6; 76:23-77:4 77:17-19 79:4-13; 79:15-80:7; 80:2-7 84:9-85:3; 85:7-13; 85:15-16; 86:23-88:18; 94:1-6; 96:22-24	F, FORM, H, I, MIS, R, V
Robert C. Moellering, Jr., M.D. (11/10/2010)	72:15-74:6	H, NARR, NR, O, PK, R, SPEC, V	76:2-4; 76:6; 76:23-77:4 77:17-19 79:4-13; 79:15-80:7; 80:2-7 84:9-85:3; 85:7-13; 85:15-16; 86:23-88:18; 94:1-6; 96:22-24	F, FORM, H, I, MIS, R, V
Robert C. Moellering, Jr., M.D. (11/10/2010)	76:7-76:9	NR, R		
Robert C. Moellering, Jr., M.D. (11/10/2010)	76:11-76:12	NR, R		

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Robert C. Moellering, Jr., M.D. (11/10/2010)	77:20-79:3	F, H, O, R, PK, SPEC	76:2-4; 76:6; 76:23-77:4 77:17-19 79:4-13; 79:15-80:7; 80:2-7; 82:4-9; 82:11-15; 82:21-83:5; 84:9-85:3; 85:7-13; 85:15-16; 86:23-88:18; 94:1-6; 96:22-24	AA, F, FORM, H, I, MIS, NR, R, V
Robert C. Moellering, Jr., M.D. (11/10/2010)	80:8-81:20	F, H, O, OB, R, PK, SPEC	76:2-4; 76:6; 76:23-77:4 77:17-19; 79:4-13; 79:15-80:7; 80:2-7; 84:9-85:3; 85:7-13; 85:15-16; 86:23-88:18; 94:1-6; 96:22-24; 81:21-25; 82:2-9; 82:11-15; 82:21-83:5	AA, F, FORM, H, I, MIS, NR, R, V
James R. Woodworth, Ph.D. (08/18/2010)	6:7-6:14			
James R. Woodworth, Ph.D. (08/18/2010)	8:7-10:13			
James R. Woodworth, Ph.D. (08/18/2010)	11:5-11:7			
James R. Woodworth, Ph.D. (08/18/2010)	12:1-12:4			
James R. Woodworth, Ph.D. (08/18/2010)	12:7-12:8			
James R. Woodworth, Ph.D. (08/18/2010)	12:10-12:23			

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
James R. Woodworth, Ph.D. (08/18/2010)	13:3-13:7			
James R. Woodworth, Ph.D. (08/18/2010)	13:9-13:17			
James R. Woodworth, Ph.D. (08/18/2010)	13:20-14:7			
James R. Woodworth, Ph.D. (08/18/2010)	14:13-16:1			
James R. Woodworth, Ph.D. (08/18/2010)	16:3-16:15	OB		
James R. Woodworth, Ph.D. (08/18/2010)	16:18-16:19			
James R. Woodworth, Ph.D. (08/18/2010)	17:13-17:16			
James R. Woodworth, Ph.D. (08/18/2010)	17:18-17:24		N	
James R. Woodworth, Ph.D. (08/18/2010)	18:2-18:22		N	
James R. Woodworth, Ph.D. (08/18/2010)	19:1-19:7		N	
James R. Woodworth, Ph.D. (08/18/2010)	19:9-19:12		N	
James R. Woodworth, Ph.D. (08/18/2010)	19:14-19:17		N	
James R. Woodworth, Ph.D. (08/18/2010)	19:19-20:6	NR, NARR, R, V, SPEC, PK		
James R. Woodworth, Ph.D. (08/18/2010)	20:8-20:23	F, NR, NARR, R, SPEC, PK		
James R. Woodworth, Ph.D. (08/18/2010)	23:5-23:10			
James R. Woodworth, Ph.D. (08/18/2010)	23:12			

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
James R. Woodworth, Ph.D. (08/18/2010)	23:21-28:8	F, H, OB, R, PK		
James R. Woodworth, Ph.D. (08/18/2010)	28:10-28:14			
James R. Woodworth, Ph.D. (08/18/2010)	29:2-29:23			
James R. Woodworth, Ph.D. (08/18/2010)	30:6-30:22			
James R. Woodworth, Ph.D. (08/18/2010)	35:15-36:8	F, H, I	34:16-35:-9, 11-14, 36:9-18, 21-37:12	DOC, F, H, SPEC
James R. Woodworth, Ph.D. (08/18/2010)	61:5-61:8	NR, R	62:2-4; 6-10, 12-14	AA, FORM, MIS, R, V
James R. Woodworth, Ph.D. (08/18/2010)	61:10-61:12	NR, R	62:2-4; 6-10, 12-14	AA, FORM, MIS, R, V
James R. Woodworth, Ph.D. (08/18/2010)	61:21-61:24	AA, R	62:2-4; 6-10, 12-14	AA, FORM, MIS, R, V
James R. Woodworth, Ph.D. (08/18/2010)	69:16-70:9	H		
James R. Woodworth, Ph.D. (08/18/2010)	71:4-72:1	H		
James R. Woodworth, Ph.D. (08/18/2010)	72:13-72:21	H	72:22-73:2	DOC
James R. Woodworth, Ph.D. (08/18/2010)	73:3-73:17	H, R	72:22-73:2; 73:18-74:14	DOC, NR, R
James R. Woodworth, Ph.D. (08/18/2010)	74:15-75:5	H, R	75:6-8; 10-15; 17-76:4; 76:6	AA, F, FORM, MIS, R
James R. Woodworth, Ph.D. (08/18/2010)	76:7-76:15	R	76:16-19, 76:21,-77:1; 77:24-78:5	F, H, MIS, DOC, V
James R. Woodworth, Ph.D. (08/18/2010)	78:19-79:5			
James R. Woodworth, Ph.D. (08/18/2010)	79:11-80:1	R		

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
James R. Woodworth, Ph.D. (08/18/2010)	80:8-80:11	R		
James R. Woodworth, Ph.D. (08/18/2010)	80:15-80:16	R		
James R. Woodworth, Ph.D. (08/18/2010)	80:21-80:24	R		
James R. Woodworth, Ph.D. (08/18/2010)	85:10-86:18	H	81:21-82:11	DOC, H, SPEC
James R. Woodworth, Ph.D. (08/18/2010)	87:11-88:8	NARR, R	81:21-82:11	DOC, H, SPEC
James R. Woodworth, Ph.D. (08/18/2010)	89:22-90:22		91:8-12	R
James R. Woodworth, Ph.D. (08/18/2010)	92:1-92:14	H, R		
James R. Woodworth, Ph.D. (08/18/2010)	92:18-93:3	H, R	93:4-8; 93:13-22; 93:24-95:12	DOC, SPEC
James R. Woodworth, Ph.D. (08/18/2010)	97:2-97:17	H, I, R	97:18-21	R
James R. Woodworth, Ph.D. (08/18/2010)	101:4			
James R. Woodworth, Ph.D. (08/18/2010)	101:8-101:22			
James R. Woodworth, Ph.D. (08/18/2010)	103:3-103:9			
James R. Woodworth, Ph.D. (08/18/2010)	103:20-104:9	R		
James R. Woodworth, Ph.D. (08/18/2010)	104:17-104:23	H, R		
James R. Woodworth, Ph.D. (08/18/2010)	106:10-106:20	R	108:9-11	DOC
James R. Woodworth, Ph.D. (08/18/2010)	106:22-108:5	NR, R	108:9-11	DOC

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
James R. Woodworth, Ph.D. (08/18/2010)	108:7-108:8	NR, R	108:9-11	DOC
James R. Woodworth, Ph.D. (08/18/2010)	109:15-110:7	H, R		
James R. Woodworth, Ph.D. (08/18/2010)	110:16-111:15	NR, R	115:7-18	DOC, F
James R. Woodworth, Ph.D. (08/18/2010)	113:3-113:14	NR, R	115:7-18	DOC, F
James R. Woodworth, Ph.D. (08/18/2010)	113:16-113:21	F, NR, R, SPEC	115:7-18	DOC, F
James R. Woodworth, Ph.D. (08/18/2010)	114:2-114:9	F, R, SPEC	115:7-18	DOC, F
James R. Woodworth, Ph.D. (08/18/2010)	114:11-114:23	F, R, SPEC	115:7-18	DOC, F
James R. Woodworth, Ph.D. (08/18/2010)	115:20-116:8	F, NR, R, O, PK, SPEC	117:23-118:6; 118:8-119:15; 119:17-24; 120:2	AA, MIS, V
James R. Woodworth, Ph.D. (08/18/2010)	116:10-117:17	F, NR, R, O, PK, SPEC	117:23-118:6; 118:8-119:15; 119:17-24; 120:2	AA, MIS, V
James R. Woodworth, Ph.D. (08/18/2010)	117:19-118:6	F, R, O, PK, SPEC	117:23-118:6; 118:8-119:15; 119:17-24; 120:2	AA, MIS, V
James R. Woodworth, Ph.D. (08/18/2010)	118:8-118:12	F, R, O, PK, SPEC	117:23-118:6; 118:8-119:15; 119:17-24; 120:2	AA, MIS, V
James R. Woodworth, Ph.D. (08/18/2010)	119:11-119:15	F, R, O, PK, SPEC	117:23-118:6; 118:8-119:15; 119:17-24; 120:2	AA, MIS, V
James R. Woodworth, Ph.D. (08/18/2010)	119:17-119:24	F, R, O, PK, SPEC	117:23-118:6; 118:8-119:15; 119:17-24; 120:2	AA, MIS, V
James R. Woodworth, Ph.D. (08/18/2010)	120:2	F, R, O, PK, SPEC	117:23-118:6; 118:8-119:15; 119:17-24; 120:2	AA, MIS, V
James R. Woodworth, Ph.D. (08/18/2010)	121:7-122:7	N	122:4-7, 9, 10-16, 22-24; 123:1	DOC, MIS
James R. Woodworth, Ph.D. (08/18/2010)	122:9	n		

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
James R. Woodworth, Ph.D. (08/18/2010)	123:7-123:9	R	108:9-11; 125:2-7, 9-14, 16-17	DOC, FORM, R, V
James R. Woodworth, Ph.D. (08/18/2010)	123:16-123:20	R	108:9-11, 125:2-7, 9-14, 16-17	DOC, FORM, R, V
James R. Woodworth, Ph.D. (08/18/2010)	123:24-124:1	R	108:9-11, 125:2-7, 9-14, 16-17; 124:2-4	DOC, FORM, R, V
James R. Woodworth, Ph.D. (08/18/2010)	124:5-125:1	H, R	108:9-11, 125:2-7, 9-14, 16-17	DOC, FORM, R, V
James R. Woodworth, Ph.D. (08/18/2010)	125:18-126:6	F, NR, R, PK, SPEC		
James R. Woodworth, Ph.D. (08/18/2010)	128:22-129:10	NR, R		
James R. Woodworth, Ph.D. (08/18/2010)	133:22-137:12	F, H, L, R, SPEC	145:9-146:2, 4	DOC, FORM, MIS, V
James R. Woodworth, Ph.D. (08/18/2010)	137:18-137:23	R		
James R. Woodworth, Ph.D. (08/18/2010)	138:1-138:13	F, R, SPEC	142:4-5, 7-8; 146:10-20, 22:147:1, 148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, NR, OB, PK, V
James R. Woodworth, Ph.D. (08/18/2010)	139:5-139:23	F, R, PK, H, SPEC	61:5-8, 10-12; 142:4-5, 7-8; 146:10-20, 22:147:1, 148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, NR, OB, PK, V
James R. Woodworth, Ph.D. (08/18/2010)	140:1-140:5	F, R, PK, H, SPEC	61:5-8, 10-12; 142:4-5, 7-8; 146:10-20, 22:147:1, 148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, NR, OB, PK, V

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
James R. Woodworth, Ph.D. (08/18/2010)	140:7-140:9	F, R, PK, SPEC	61:5-18, 10-12; 142:4-5, 7-8; 146:10-20, 22:147:1, 148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, NR, OB, PK, V
James R. Woodworth, Ph.D. (08/18/2010)	140:11-142:3	F, H, R, PK, SPEC	61:5-8, 10-12; 142:4-5, 7-8; 146:10-20, 22:147:1, 148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, NR, OB, PK, V
James R. Woodworth, Ph.D. (08/18/2010)	142:9-142:15	F, L, R, PK, SPEC	142:4-5, 7-8; 146:10-20, 22:147:1, 148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, NR, OB, PK, V
James R. Woodworth, Ph.D. (08/18/2010)	142:18-142:21	F, L, I, R, PK, SPEC	142:4-5, 7-8; 146:10-20, 22:147:1, 148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, NR, OB, PK, V
James R. Woodworth, Ph.D. (08/18/2010)	142:23-143:7	F, L, R, PK, SPEC	142:4-5, 7-8; 146:10-20, 22:147:1, 148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, NR, OB, PK, V
James R. Woodworth, Ph.D. (08/18/2010)	144:2-145:4	NR, R	145:10-146:2; 146:4-16, 18-20, 22-147:1; 146:10-20, 22:147:1, 148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, NR, OB, V
James R. Woodworth, Ph.D. (08/18/2010)	145:6-145:8		145:10-146:2; 146:4-16, 18-20, 22-147:1	FORM, NR, V
James R. Woodworth, Ph.D. (08/18/2010)	147:2-147:13	F, R, PK, SPEC	148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, OB, V

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
James R. Woodworth, Ph.D. (08/18/2010)	147:15-147:19	F, R, PK, SPEC	148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, OB, V
James R. Woodworth, Ph.D. (08/18/2010)	147:23-148:4	F, R, PK, SPEC	148:20-22; 148:23-149:6, 149:8-14, 149:18-23, 150:1	AA, F, FORM, H, MIS, OB, V
Richard H. Baltz, Ph.D. (7/25/2013)	5:10-5:16			
Richard H. Baltz, Ph.D. (7/25/2013)	14:6-14:9		14:10-11; 14:13-15; 14:17-24; 15:13-22	R
Richard H. Baltz, Ph.D. (7/25/2013)	28:12-29:2	I, V, PK, SPEC, H	29:16-20, 29:22-30:9; 145:8-10; 145:17-146:1; 146:3-9; 140:12-142:3; 144:18-145:10; 145:17-146:1; 146:3-22;148:7-10; 151:21-23; 152:1-3; 179:14-181:14; 182:20-23; 183:1-16; 213:21-214:8; 218:9-12; 218:22-219:14, 219:21-24; 220:1-4, 6-9; 221:8-12; 221:14-222:6; 222:8-10; 222:11-15	DOC, F, FORM, LO, MIS, R, V

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Richard H. Baltz, Ph.D. (7/25/2013)	29:4-29:15	O, R, PK, SPEC, H	29:16-20, 29:22-30:9; 145:8-10; 145:17-146:1; 146:3-9; 140:12-142:3; 144:18-145:10; 145:17-146:1; 146:3-22; 148:7-10; 151:21-23; 152:1-3; 179:14-181:14; 182:20-23; 183:1-16; 213:21-214:8; 218:9-12; 218:22-219:14, 219:21-24; 220:1-4, 6-9; 221:8-12; 221:14-222:6; 222:8-10; 222:11-15	DOC, F, FORM, LO, MIS, R, V
Richard H. Baltz, Ph.D. (7/25/2013)	30:10-30:12	NR, NARR, R	29:16-20, 29:22-30:9; 145:8-10; 145:17-146:1; 146:3-9; 140:12-142:3; 144:18-145:10; 145:17-146:1; 146:3-22; 148:7-10; 151:21-23; 152:1-3; 179:14-181:14; 182:20-23; 183:1-16; 213:21-214:8; 218:9-12; 218:22-219:14, 219:21-24; 220:1-4, 6-9; 221:8-12; 221:14-222:6; 222:8-10; 222:11-15	DOC, F, FORM, LO, MIS, R, V

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Richard H. Baltz, Ph.D. (7/25/2013)	30:14-31:2	NR, NARR, R	29:16-20, 29:22-30:9; 145:8-10; 145:17-146:1; 146:3-9; 148:7-10; 151:21-23; 152:1-3; 140:12-142:3; 144:18-145:10; 145:17-146:1; 146:3-22; 179:14-181:14; 182:20-23; 183:1-16; 213:21-214:8; 218:9-12; 218:22-219:14, 219:21-24; 220:1-4, 6-9; 221:8-12; 221:14-222:6; 222:8-10; 222:11-15	DOC, F, FORM, LO, MIS, R, V
Richard H. Baltz, Ph.D. (7/25/2013)	33:20-34:2	F, NR, R, PK, SPEC	33:8-19; 56:17-19; 205:5-16; 205:18-19; 206:11-15; 206:18; 210:12-212:3	F, LO, MIS, R, V
Richard H. Baltz, Ph.D. (7/25/2013)	34:4-34:8	F, NR, R, PK, SPEC	33:8-19; 56:17-19 205:5-16; 205:18-19; 206:11-15; 206:18; 210:12-212:3	F, LO, MIS, R, V
Richard H. Baltz, Ph.D. (7/25/2013)	34:16-34:19	F, NR, R, PK, SPEC	33:8-19; 56:17-19 205:5-16; 205:18-19; 206:11-15; 206:18; 210:12-212:3	F, LO, MIS, R, V
Richard H. Baltz, Ph.D. (7/25/2013)	34:21-34:23	F, NR, R, PK, SPEC	33:8-19; 56:17-19 205:5-16; 205:18-19; 206:11-15; 206:18; 210:12-212:3	F, LO, MIS, R, V

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Richard H. Baltz, Ph.D. (7/25/2013)	55:13-57:13			
Richard H. Baltz, Ph.D. (7/25/2013)	60:9-60:10			
Richard H. Baltz, Ph.D. (7/25/2013)	60:13-60:21			
Richard H. Baltz, Ph.D. (7/25/2013)	71:10-72:16	F, NR, O, R, PK, SPEC	29:16-20, 29:22-30:9; 145:8-10; 145:17-146:1; 146:3-9; 140:12-142:3; 144:18-145:10; 145:17-146:1; 146:3-22; 148:7-10; 151:21-23; 152:1-3; 173:13-15; 173:17-24; 174:2-4; 179:14-181:14; 182:20-23; 183:1-16; 213:21-214:8; 218:9-12; 218:22-219:14, 219:21-24; 220:1-4, 6-9; 221:8-12; 221:14-222:6; 222:8-10; 222:11-15	DOC, F, FORM, LO, MIS, R, V

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Richard H. Baltz, Ph.D. (7/25/2013)	73:17-74:1	F, NR, NARR, R, PK	29:16-20, 29:22-30:9; 74:16-75:3; 145:8-10; 145:17-146:1; 146:3-9; 140:12-142:3; 144:18-145:10; 145:17-146:1; 146:3-22; 148:7-10; 151:21-23; 152:1-3; 173:13-15; 173:17-24; 174:2-4; 179:14-181:14; 182:20-23; 183:1-16; 213:21-214:8; 218:9-12; 218:22-219:14, 219:21-24; 220:1-4, 6-9; 221:8-12; 221:14-222:6; 222:8-10; 222:11-15	AA, DOC, F, FORM, LO, MIS, R, V

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Richard H. Baltz, Ph.D. (7/25/2013)	87:24-88:11	NR, O, R	29:16-20, 29:22-30:9; 145:8-10; 145:17-146:1; 146:3-9; 140:12-142:3; 144:18-145:10; 145:17-146:1; 146:3-22; 148:7-10; 151:21-23; 152:1-3; 173:13-15; 173:17-24; 174:2-4; 179:14-181:14; 182:20-23; 183:1-16; 213:21-214:8; 218:9-12; 218:22-219:14, 219:21-24; 220:1-4, 6-9; 221:8-12; 221:14-222:6; 222:8-10; 222:11-15	DOC, F, FORM, LO, MIS, R, V
Richard H. Baltz, Ph.D. (7/25/2013)	89:9-90:2	I		
Richard H. Baltz, Ph.D. (7/25/2013)	112:5-112:9	F, I, H, PK, SPEC	33:8-19; 56:17-19 205:5-16; 205:18-19; 206:11-15; 206:18; 210:12-212:3	F, MIS, R, V
Michael Zeckel (9/23/2010)	7:16 – 7:21			
Michael Zeckel (9/23/2010)	10:25 – 11:21			
Michael Zeckel (9/23/2010)	13:8 – 13:12	R	24:22-24; 25:16-18	AA, R
Michael Zeckel (9/23/2010)	13:15 – 13:18	R	24:22-24; 25:16-18	AA, R
Michael Zeckel (9/23/2010)	14:18 – 15:25	R	24:22-24; 25:16-18	AA, R
Michael Zeckel (9/23/2010)	16:17 – 16:21	R	24:22-24; 25:16-18	AA, R
Michael Zeckel (9/23/2010)	18:16 – 18:23	I		
Michael Zeckel (9/23/2010)	19:5 – 19:20	R	26:6-10, 19-21	AA, R

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Michael Zeckel (9/23/2010)	23:17 – 24:4	F, R, H, PK, O, SPEC	24:10-17, 22-24; 25:16-18	AA, R
Michael Zeckel (9/23/2010)	24:10 – 24:17			
Michael Zeckel (9/23/2010)	27:11 – 28:6		28:7-12; 31:8-13	
Michael Zeckel (9/23/2010)	29:17 – 30:4			
Michael Zeckel (9/23/2010)	31:14 – 32:2		35:14-20; 35:22-36:2; 36:4-5	F, FORM, R, SPEC, V
Michael Zeckel (9/23/2010)	32:15 – 32:16			
Michael Zeckel (9/23/2010)	32:18 – 32:25			
Michael Zeckel (9/23/2010)	35:6 – 35:13	I	35:16-17	I
Michael Zeckel (9/23/2010)	37:3 – 37:19			
Michael Zeckel (9/23/2010)	37:25 – 38:21			
Michael Zeckel (9/23/2010)	65:7 – 65:9	F, PK, R, SPEC		
Michael Zeckel (9/23/2010)	65:24 – 66:2	F, O, PK, R, SPEC	66:3-16	F, SPEC, V
Michael Zeckel (9/23/2010)	69:10 – 69:23			
Michael Zeckel (9/23/2010)	70:12 – 70:20			
Michael Zeckel (9/23/2010)	71:7 – 71:15		71:2-6	DOC
Michael Zeckel (9/23/2010)	73:16 – 73:24		71:23-72:16; 73:4-15	DOC, F, H, SPEC, V
Michael Zeckel (9/23/2010)	74:23 – 75:11	F, H, O, PK, SPEC		
Michael Zeckel (9/23/2010)	79:8 – 80:25			
Michael Zeckel (9/23/2010)	81:17 – 81:22		81:11-16	DOC
Michael Zeckel (9/23/2010)	83:18 – 84:9		84:7-9, 11-17	
Michael Zeckel (9/23/2010)	84:11 – 84:17			
Michael Zeckel (9/23/2010)	100:14 – 101:9	F, O, PK, R, SPEC	36:1-2, 36:4-12, 55:15-56:13, 99:15-100:13, 101:10-17; 101:18-22; 101:24-102:13	DOC, FORM, H, MIS, R, V
Michael Zeckel (9/23/2010)	102:14 – 102:24			
Michael Zeckel (9/23/2010)	103:6 – 103:9	F, PK, R, SPEC		
Michael Zeckel (9/23/2010)	103:11 – 103:18	F, PK, R, SPEC		

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Michael Zeckel (9/23/2010)	103:24 – 105:19	F, H, PK, R, SPEC	55:15-56:13, 104:7-10; 105:20-25; 106:2-4	FORM, R, SPEC, V
Michael Zeckel (9/23/2010)	110:5 – 110:21	F, NR, PK, R, SPEC		
Michael Zeckel (9/23/2010)	111:2 – 112:6	NR, R		
Michael Zeckel (9/23/2010)	112:8 – 112:17	F, H, R, O, SPEC	112:18-22	DOC, H, MIS, V
Michael Zeckel (9/23/2010)	113:6 – 114:1	R		
Michael Zeckel (9/23/2010)	115:14 – 116:2		119:18-120:13; 134:11-135:16; 136:24-137:9; 137:20-138:18; 138:24-139:14	AA, ARG, DOC, F, FORM, H, MIS, NR, SPEC, V
Michael Zeckel (9/23/2010)	121:6 – 122:1	H, R	122:2-12; 122:14-123:6;123:8-9	AA, DOC, O, MIS, SPEC, V
Michael Zeckel (9/23/2010)	123:12 – 123:21	H, R	122:2-12; 122:14-123:6;123:8-9; 1	AA, DOC, O, MIS, SPEC, V
Michael Zeckel (9/23/2010)	124:10 – 124:21	H, R	122:2-12; 122:14-123:6;123:8-9	AA, DOC, O, MIS, SPEC, V
Michael Zeckel (9/23/2010)	124:23 – 124:25	R	122:2-12; 122:14-123:6;123:8-9	AA, DOC, O, MIS, SPEC, V
Michael Zeckel (9/23/2010)	131:21 – 132:25	F, R, PK, SPEC	134:11-135:16, 135:20-136:4; 136:7-137:9, 137:20-138:7, 138:9-139:14	AA, DOC, F, FORM H, MIS, NR, SPEC, V
Michael Zeckel (9/23/2010)	133:11 – 133:15	F, O, PK, R	134:11-135:16, 135:20-136:4; 136:7-137:9, 137:20-138:7, 138:9-139:14	AA, DOC, F, FORM H, MIS, NR, SPEC, V
Michael Zeckel (9/23/2010)	133:17 – 134:10	NR, F, O, PK, R	134:11-135:16, 135:20-136:4; 136:7-137:9, 137:20-138:7, 138:9-139:14	AA, DOC, F, FORM H, MIS, NR, SPEC, V
Michael Zeckel (9/23/2010)	164:6 – 164:9	R	167:13-168:10, 168:23-169:13	F, H, MIS, SPEC

Witness (Date)	Cubist's Designation	Hospira's Objection(s) to Cubist's Designation	Hospria's Counter-Designation to Cubist's Designation	Cubist's Objection(s) to Hospira's Counter-Designation
Michael Zeckel (9/23/2010)	164:22 – 165:3	H, L, R, SPEC	167:13-168:10, 168:23-169:13	F, H, MIS, SPEC
Michael Zeckel (9/23/2010)	165:5 – 165:11	L, NR, R	167:13-168:10, 168:23-169:13	F, H, MIS, SPEC
Michael Zeckel (9/23/2010)	165:13 – 165:16	L, R, SPEC	167:13-168:10, 168:23-169:13	F, H, MIS, SPEC
Michael Zeckel (9/23/2010)	165:18 – 166:3	NR, NARR, R, SPEC	167:13-168:10, 168:23-169:13	F, H, MIS, SPEC
Michael Zeckel (9/23/2010)	166:5 – 166:6	BTS, R, SPEC	167:13-168:10, 168:23-169:13	F, H, MIS, SPEC
Michael Zeckel (9/23/2010)	166:8 – 166:11	BTS, R, SPEC	167:13-168:10, 168:23-169:13	F, H, MIS, SPEC
Michael Zeckel (9/23/2010)	166:14 – 166:22	BTS, F, R, PK, SPEC	167:13-168:10, 168:23-169:13	F, H, MIS, SPEC
Michael Zeckel (9/23/2010)	166:24 – 167:5	BTS, NR, O, R	167:13-168:10, 168:23-169:13	F, H, MIS, SPEC

EXHIBIT 11

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

CUBIST PHARMACEUTICALS, INC., Plaintiff, v. HOSPIRA, INC., Defendant.	Civil Action No. 12-367-GMS (CONSOLIDATED)

HOSPIRA'S INITIAL DEPOSITION TESTIMONY DESIGNATIONS

Hospira may introduce the follow deposition testimony at trial, consistent with the Federal Rules of Evidence and Federal Rules of Civil Procedure, subject to objections as to admissibility. Hospira reserves its right to determine which, if any, portions of these designations shall be read into the record (or, where videotaped, played into the record). Hospira's designations are not a waiver of any right to object to Cubist's introduction of the same testimony.

This document incorporates the following abbreviations for objections to deposition designations:

Code	Objection
ARG	**Lawyer Argument or Colloquy.** Cubist objectss to this deposition designation because it is lawyer argument and not testimony of the witness.
CM	**Cumulative.** Cubist objects to this deposition designation on the ground that it is duplicative and/or cumulative of other designations.
D	**Not Produced During Discovery.** Cubist objects to this deposition designation because the question asks the witness to offer testimony on a document that was not produced during the course of discovery.
DOC	**Document Speaks For Itself.** Cubist objects to this deposition designation because the question asks the witness to offer testimony on a document that speaks for itself.
F	**Foundation.** Cubist objects to this deposition designation on the ground that the foundation necessary for its admission has not been laid. (Fed. R. Evid. 602)
FORM	**Form.** Cubist objects to this deposition designation because the question asked is compound, leading, or has some other defect in form.

Code	Objection
FRE 106	**Remainder of or Related Writings or Recorded Statements.** Cubist objects to this deposition designation because it asks the witness to offer testimony on a document where the remainder of the document should fairly be considered. (Fed. R. Evid. 106)
H	**Hearsay.** Cubist objects to this deposition designation because it constitutes or contains hearsay. (Fed. R. Evid. 801-802)
I	**Incomplete.** Cubist objects to this deposition designation because it does not contain the complete testimony. (Fed. R. Evid. 106) Cubist generally object to all designations that include only part of a question and/or part of an answer, or that do not include any question.
IR	**Not Relevant.** Cubist objects to this deposition designation because it is not relevant to any issue to be decided in this case. (Fed. R. Evid. 401-402)
LC	**Legal Conclusion.** Cubist objects to this deposition designation because it contains conclusions of law.
LO	**Lay Opinion.** Cubist objects to this deposition designation because it constitutes or contains improper opinion by a lay witness. (Fed. R. Evid. 701-702)
M	**Mischaracterization.** Cubist objects to this deposition designation because the question asked mischaracterizes the witness's prior testimony and/or the question asked (or the testimony provided) mischaracterizes the document being shown to the witness.
NN	**Not Noticed In an Individual Capacity.** Cubist objects to this deposition designation because the witness was not noticed for deposition in an individual capacity.
NR	**Non-Responsive Testimony.** Cubist objects to this deposition designation because it includes statements that are not responsive to the question asked.
PRIV	**Privileged.** Cubist objects to this deposition designation because it seeks communications or information protected from disclosure by the attorney-client privilege, work product doctrine, common interest, joint defense, and/or other privilege.
S	**Speculative.** Cubist objects to this deposition designation because it includes statements that are speculative as to matters of fact or law.
SCOPE	**Beyond Scope of 30(b)(6) Notice or Topics.** Cubist objects to this deposition designation because it is outside the scope of the topics on which the witness was designated as a corporate representative.
UP	**Unfair Prejudice.** Cubist objects to this deposition designation because its probative value is outweighed by unfair prejudice and/or confusion of the issues. (Fed. R. Evid. 403)

Code	Objection
VA	**Vague and Ambiguous.** Cubist objects to this deposition designation because it includes vague and indefinite statements.

Patrick Baker 07/28/2010 (Teva)

Deponent	Deposition Date	Defendant's Trial Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendant's Objections to Counters and Counter Counter Designation
Baker, Patrick	07/28/2010	5:13 - 5:14			
Baker, Patrick	07/28/2010	7:18 - 7:23			
Baker, Patrick	07/28/2010	8:2 - 8:12			
Baker, Patrick	07/28/2010	8:16 - 8:18			
Baker, Patrick	07/28/2010	8:25 - 9:5			
Baker, Patrick	07/28/2010	13:13 - 13:20	IR		
Baker, Patrick	07/28/2010	14:1 - 14:7	IR		
Baker, Patrick	07/28/2010	14:20 - 14:23	IR		
Baker, Patrick	07/28/2010	15:23 - 16:1	IR		
Baker, Patrick	07/28/2010	16:6 - 16:7	IR, S, H		
Baker, Patrick	07/28/2010	16:10 - 16:24	IR		
Baker, Patrick	07/28/2010	17:4 - 17:6	IR		
Baker, Patrick	07/28/2010	17:24 - 18:18			
Baker, Patrick	07/28/2010	22:8 - 22:11			
Baker, Patrick	07/28/2010	22:15 - 22:18			
Baker, Patrick	07/28/2010	25:13 - 25:17			
Baker, Patrick	07/28/2010	26:2 - 26:13			
Baker, Patrick	07/28/2010	26:23 - 27:5	IR, DOC		
Baker, Patrick	07/28/2010	28:9 - 28:12	IR		
Baker, Patrick	07/28/2010	28:14 - 28:15	IR		
Baker, Patrick	07/28/2010	30:7 - 30:9	IR, DOC		
Baker, Patrick	07/28/2010	30:15 - 30:18	IR, DOC		
Baker, Patrick	07/28/2010	30:23 - 31:3			
Baker, Patrick	07/28/2010	31:6 - 31:8			
Baker, Patrick	07/28/2010	31:12 - 31:14			
Baker, Patrick	07/28/2010	32:6 - 32:13			
Baker, Patrick	07/28/2010	33:14 - 33:22	I	33:23-24	
Baker, Patrick	07/28/2010	34:11 - 34:23		35:7-22	

Deponent	Deposition Date	Defendant's Trial Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendant's Objections to Counters and Counter Counter Designation
Baker, Patrick	07/28/2010	36:11 - 36:14			
Baker, Patrick	07/28/2010	37:2 - 37:9		36:15-37:1	
Baker, Patrick	07/28/2010	38:8 - 39:1	I	39:2-12	
Baker, Patrick	07/28/2010	39:19 - 39:24	LO, S		
Baker, Patrick	07/28/2010	40:1 - 40:24	LO, S		
Baker, Patrick	07/28/2010	44:19 - 44:22	IR, DOC		
Baker, Patrick	07/28/2010	45:3 - 45:7	IR, DOC		
Baker, Patrick	07/28/2010	47:24 - 48:1	LO		
Baker, Patrick	07/28/2010	48:6 - 49:2	LO, H, DOC		
Baker, Patrick	07/28/2010	49:19 - 50:16			
Baker, Patrick	07/28/2010	51:24 - 52:9			
Baker, Patrick	07/28/2010	53:1 - 54:5	H, DOC	90:12-91:3	
Baker, Patrick	07/28/2010	54:7 - 54:25	H, DOC	90:12-91:3	
Baker, Patrick	07/28/2010	55:4 - 56:10	H, DOC	90:12-91:3	
Baker, Patrick	07/28/2010	56:12 - 57:8	H, DOC	90:12-91:3	
Baker, Patrick	07/28/2010	57:11 - 57:17	H, DOC	90:12-91:3	
Baker, Patrick	07/28/2010	57:20 - 58:7	H, DOC	90:12-91:3	
Baker, Patrick	07/28/2010	61:19 - 61:22	IR, H	98:12-99:25	
Baker, Patrick	07/28/2010	62:6 - 63:15	H, DOC	98:12-99:25	
Baker, Patrick	07/28/2010	64:3 - 64:17	H, DOC	98:12-99:25	
Baker, Patrick	07/28/2010	64:23 - 65:1	H, DOC	98:12-99:25	
Baker, Patrick	07/28/2010	72:2 - 72:9	H, DOC	98:12-99:25	
Baker, Patrick	07/28/2010	81:4 - 81:23	R, DOC		
Baker, Patrick	07/28/2010	84:21 - 85:9			
Baker, Patrick	07/28/2010	85:15 - 86:9			
Baker, Patrick	07/28/2010	86:22 - 87:1			
Baker, Patrick	07/28/2010	87:14 - 87:23	LO, H, DOC		
Baker, Patrick	07/28/2010	87:25 - 89:23	LO, H, DOC	89:24-90:11	100:8 – 102:8
Baker, Patrick	07/28/2010	91:4 - 93:13	IR		
Baker, Patrick	07/28/2010	93:15 - 93:18	IR		

Patrick Baker 07/09/2013

Deponent	Deposition Date	Defendant's Trial Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendant's Objections to Counters and Counter Counter Designation
Baker, Patrick	07/09/13	5:9 - 5:10			
Baker, Patrick	07/09/13	8:5 - 8:10			
Baker, Patrick	07/09/13	8:18 - 8:20			
Baker, Patrick	07/09/13	11:4 - 11:10			
Baker, Patrick	07/09/13	16:6 - 16:13	I, IR, LO, M	16:14-17:1	
Baker, Patrick	07/09/13	17:2 - 17:21	I, IR, LO, M	17:24-18:15; 20:16-24; 21:1-3; 21:5-23	
Baker, Patrick	07/09/13	26:16 - 27:21	IR	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	28:13 - 29:4	I	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	29:21 - 30:16	IR	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	30:20 - 30:23			
Baker, Patrick	07/09/13	31:2 - 32:1	IR, DOC		
Baker, Patrick	07/09/13	32:6 - 33:1	IR, DOC		
Baker, Patrick	07/09/13	33:5 - 33:18	IR		
Baker, Patrick	07/09/13	33:25 - 34:12	IR		
Baker, Patrick	07/09/13	34:19 - 35:3	IR	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	35:5 - 36:19	IR, DOC, LC, LO, M	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	

Deponent	Deposition Date	Defendant's Trial Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendant's Objections to Counters and Counter Counter Designation
Baker, Patrick	07/09/13	49:9 - 49:10	IR, DOC, LC, LO, M	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	49:15 - 49:21	IR, DOC, LC, LO, M	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	49:23 - 49:25	IR, DOC, LC, LO, M	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	50:7 - 50:14	IR, DOC, LC, LO, M	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	51:1 - 51:14	IR, DOC, LC, LO, M	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	53:2 - 53:6	IR, LC, UP	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	53:8 - 53:16	IR, LC, UP	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	53:21 - 54:1	IR, LC, UP	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	54:7 - 54:25	IR, LC, UP	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
Baker, Patrick	07/09/13	55:2 - 55:13	IR, LC, UP, LO	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	

Deponent	Deposition Date	Defendant's Trial Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendant's Objections to Counters and Counter Counter Designation
Baker, Patrick	07/09/13	55:15 - 55:19	IR, LO, M, VA, F	27:22-24; 29:8-14; 29:17-20; 50:15-23; 50:25; 52:3-15; 52:17-21	
				56:9-57:8	F, H, O, PK, SPEC
Baker, Patrick	07/09/13	57:21 - 58:1	M, LO, IR, VA	44:16-45:6	BTS, SPEC
Baker, Patrick	07/09/13	58:25 - 59:14	M, LO, IR, VA	46:16-17	O, NARR, I, R 46:19-20
				46:21-48:10	O, NARR, I, R
				48:12-48:22	O, NARR, I, R
				48:23 – 49:2	
Baker, Patrick	07/09/13	59:17 - 59:20	M, LO, IR, VA	61:8:10; 61:12-14; 61:24-62:11; 62:13; 62:15-63:6; 64:8-65:15; 66:11-68:17	
Baker, Patrick	07/09/13	60:13 - 60:16	M, LO, IR, VA	61:8:10; 61:12-14; 61:24-62:11; 62:13; 62:15-63:6; 64:8-65:15; 66:11-68:17	
Baker, Patrick	07/09/13	61:3 - 61:7	M, LO, IR, VA, I	61:8:10; 61:12-14; 61:24-62:11; 62:13; 62:15-63:6; 64:8-65:16; 66:11-68:17	
Baker, Patrick	07/09/13	61:15 - 61:18	M, LO, IR, VA, I, S	61:8:10; 61:12-14; 61:24-62:11; 62:13; 62:15-63:6; 64:8-65:16; 66:11-68:17	
Baker, Patrick	07/09/13	61:20 - 61:23	M, LO, IR, VA, I, S	61:8:10; 61:12-14; 61:24-62:11; 62:13; 62:15-63:6; 64:8-65:16; 66:11-68:17	
Baker, Patrick	07/09/13	63:7 - 63:9	M, LO, IR, VA, I, S	61:8:10; 61:12-14; 61:24-62:11; 62:13; 62:15-63:6; 64:8-65:16; 66:11-68:17	

Deponent	Deposition Date	Defendant's Trial Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendant's Objections to Counters and Counter Counter Designation
Baker, Patrick	07/09/13	63:12 - 63:22	M, LO, IR, VA, I, S	61:8:10; 61:12-14; 61:24-62:11; 62:13; 62:15-63:6; 64:8-65:16; 66:11-68:17	

Richard H. Baltz 05/14/2010 (Teva)

Deponent	Deposition Date	Defendant's Trial Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendant's Objections to Plaintiff's Counter-Designations
Baltz, Richard	05/14/2010	6:22 - 7:2			
Baltz, Richard	05/14/2010	7:7 - 7:15			
Baltz, Richard	05/14/2010	13:20 - 13:24			
Baltz, Richard	05/14/2010	14:1 - 14:21			
Baltz, Richard	05/14/2010	16:3 - 16:16			
Baltz, Richard	05/14/2010	17:2 - 17:13			
Baltz, Richard	05/14/2010	17:21 - 17:25			
Baltz, Richard	05/14/2010	18:3 - 18:16			
Baltz, Richard	05/14/2010	19:1 - 19:17			
Baltz, Richard	05/14/2010	20:3 - 20:14			
Baltz, Richard	05/14/2010	20:21 - 21:1			
Baltz, Richard	05/14/2010	21:13 - 22:11			
Baltz, Richard	05/14/2010	22:23 - 23:12	I	23:13-24:13	NR, R, ID
Baltz, Richard	05/14/2010	34:18 - 34:24			
Baltz, Richard	05/14/2010	35:5 - 35:16			
Baltz, Richard	05/14/2010	39:9 - 39:15			
Baltz, Richard	05/14/2010	39:20 - 40:16			
Baltz, Richard	05/14/2010	42:9 - 42:20			
Baltz, Richard	05/14/2010	43:5 - 43:25			
Baltz, Richard	05/14/2010	44:8 - 44:11			

Deponent	Deposition Date	Defendant's Trial Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendant's Objections to Plaintiff's Counter-Designations
Baltz, Richard	05/14/2010	49:10 - 49:18			
Baltz, Richard	05/14/2010	52:3 - 52:13			
Baltz, Richard	05/14/2010	53:5 - 53:11			
Baltz, Richard	05/14/2010	56:6 - 56:10			
Baltz, Richard	05/14/2010	56:13 - 56:20			
Baltz, Richard	05/14/2010	67:16 - 67:18			
Baltz, Richard	05/14/2010	69:17 - 70:17	F		
Baltz, Richard	05/14/2010	70:19 - 71:5	F		
Baltz, Richard	05/14/2010	71:22 - 72:17			
Baltz, Richard	05/14/2010	72:19 - 72:24			
Baltz, Richard	05/14/2010	75:20 - 75:25			
Baltz, Richard	05/14/2010	76:3 - 76:9	H, DOC		
Baltz, Richard	05/14/2010	80:4 - 80:17	DOC		
Baltz, Richard	05/14/2010	81:2 - 83:4			
Baltz, Richard	05/14/2010	83:6 - 84:6			
Baltz, Richard	05/14/2010	84:19 - 85:2			
Baltz, Richard	05/14/2010	85:9 - 85:17	FORM, VA, F		
Baltz, Richard	05/14/2010	85:19	FORM, VA, F		
Baltz, Richard	05/14/2010	95:13 - 95:22			
Baltz, Richard	05/14/2010	96:4 - 96:9			
Baltz, Richard	05/14/2010	96:11 - 96:21	M, DOC, FORM, VA		
Baltz, Richard	05/14/2010	96:23	M, DOC, FORM, VA		
Baltz, Richard	05/14/2010	97:1 - 98:16	DOC		
Baltz, Richard	05/14/2010	99:6 - 99:15	DOC, FORM, VA		
Baltz, Richard	05/14/2010	99:17 - 99:25	DOC, FORM, VA, F		
Baltz, Richard	05/14/2010	100:2 - 100:11	FORM, VA, F		
Baltz, Richard	05/14/2010	101:7 - 101:13	I	101:14-101:25	AA, ID
Baltz, Richard	05/14/2010	103:13 - 104:24	DOC		
Baltz, Richard	05/14/2010	105:14 - 105:17	DOC, FORM, M		
Baltz, Richard	05/14/2010	105:19 - 106:6	DOC		